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ABSTRACT
Drug delivery refers to approaches, formulations, technologies, and systems for 
transporting a drug in the body. The purpose is to enhance the drug efficacy and to reduce 
side reactions, which can significantly improve treatment outcomes. Halloysite is a 
naturally occurred alumino-silicate clay with a tubular structure. It is a biocompatible 
material with a big surface area which can be used for attachment o f targeted molecules. 
Besides, loaded molecules can present a sustained release manner in solution. These 
properties make halloysite nanotubes (HNTs) a good option for drug delivery.
In this study, a drug delivery system was built based on halloysite via three 
different fabrication methods: physical adsorption, vacuum loading and layer-by-layer 
coating. Methotrexate was used as the model drug. Factors that may affect performance 
in both drug loading and release were tested. Results showed that methotrexate could be 
incorporated within the HNTs system and released in a sustained manner. Layer-by-layer 
coating showed a better potential than the other two methods in both MTX loading and 
release. Besides, lower pH could greatly improve MTX loading and release while the 
increased number o f polyelectrolytes bilayers had a limited impact.
Osteosarcoma is the most common primary bone malignancy in children and 
adolescents. Postoperative recurrence and metastasis has become one o f the leading 
causes for patient death after surgical remove o f the tumor mass. A strategy could be a 
sustained release o f  chemotherapeutics directly at the primary tumor sites where
recurrence would mostly occur. Then, this HNTs based system was tested with 
osteosarcoma cells in vitro to show the potential o f  delivering chemotherapeutics in the 
treatment o f osteosarcoma. Methotrexate was incorporated within HNTs with a layer-by- 
layer coating technique, and drug coated HNTs were filled into nylon - 6  which is a 
common material for surgical sutures in industry. Results showed that (1) methotrexate 
could be released in a sustained manner; (2 ) cytotoxicity test confirmed the 
biocompatibility o f HNTs and methotrexate coated HNTs; (3) proliferation test 
confirmed the growth inhibition o f  released methotrexate on osteosarcoma cells; and (4) 
nylon - 6  could prolong the sustained release o f methotrexate from polyelectrolytes coated 
HNTs.
Another application comes from the prevention o f  surgical site infection. It is a 
common complication in surgery, which may prolong hospital stay, increase mortality 
rate, and cause additional financial burden for patients. By directly releasing antibiotics at 
the surgical site, it is supposed to enhance the drug efficacy and improve the treatment 
outcome. Therefore, the same HNTs based system was tested with E. coli in vitro to show 
the potential o f  delivering antibiotics to enhance the prevention o f surgical site infection. 
Nitrofurantoin was incorporated within HNTs using the layer-by-layer coating technique, 
and the drug coated HNTs were filled into nylon - 6  again. Results showed that (1) 
nitrofurantoin could be incorporated with this HNTs based drug delivery system, and 
released in a sustained manner; (2 ) nylon - 6  could prolong the sustained release o f 
nitrofurantoin from polyelectrolytes coated HNTs; and (3) released nitrofurantoin could 
severely inhibit E. coli growth.
Therefore, a tunable drug delivery system based on HNTs was developed, and a 
great potential o f  medical application in drug delivery was shown.
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CHAPTER 1
INTRODUCTION
1.1 Objective
This dissertation introduces a newly formed drug delivery system based on 
halloysite nanotubes (HNTs). By applying several fabrication methods, biologically 
functional molecules (such as DNA, RNA, proteins, and drugs) could be loaded within 
this nano-vehicle, and released in a sustained/controlled manner at the sites o f action. 
Subsequently, these released molecules could act on the surrounding tissues or cells. In 
this way, biomolecules can be directly delivered to their action sites, which would 
increase their efficacy and safety, and avoid potential side reactions as well.
1.2 Background
1.2.1 Nanotechnology
In the 21st Century, nanotechnology has become one o f the leading elements 
advancing technology, and nanotech-based products have impacted almost everything we 
touch in life, such as medicines, chemicals, biologies, and pharmaceuticals [1]. In 
particular, the breakthroughs o f  nano-engineering made in the field o f drug delivery and 
formulation development have contributed significantly to the growth o f 
nanopharmaceuticals [2]. Because o f the inherent potential o f nanopharmaceutical 
products to overcome solubility and stability issues, localized drug delivery, enhanced
2drug efficacy, the need to avoid unwanted side reactions, and assistance in diagnosis via 
in vivo imaging, increased research efforts have been focused on the specific fields o f 
drug delivery and formulation.
1.2.2 Drug Delivery
During the past few years, an increased number o f researchers have realized the 
importance o f  effective drug delivery, which is a fundamental part o f drug development. 
Many drug delivery systems have been developed and have entered the market, such as 
liposomes and nanoparticles. Theoretically speaking, an ideal drug delivery system 
should improve the stability, absorption, and therapeutic concentration o f the drug within 
the target environment, as well as the long-term release o f the drug at the target site. 
Additionally, it should help reduce the frequency o f drug administration and improve 
patient comfort [ 1 ].
1.2.3 Market Need
In the pharmaceutical industry, the field o f drug delivery offers a new direction 
for expanding drug markets, because newly developed nanotechnology could assist in 
making current drugs more efficacious and improve their competition against other 
counterparts. In 2012, it was estimated that about 13% o f the global pharmaceutical 
market was related to the sale o f products based on a drug delivery system [3],
1.3 Specific Aims
In this dissertation, a halloysite-based drug delivery system was developed with 
different fabrication methods. Factors that could affect the loading and releasing process 
were tested to obtain more control over the newly formed nano-vehicle. Three fabrication 
methods were compared in the performance o f  both loading and release results. The best
3method was used in subsequent experiments. Two individual in vitro tests were used to 
verify the potential o f using an HNT based system for drug delivery. Methotrexate 
(MTX) and nitrofurantoin (NFT) were used as model drugs, and osteosarcoma cells and 
Escherichia coli (E. coli) were used for tested targets to individually show the feasibility 
in the treatment o f osteosarcoma and surgical site infection.
1.4 Projects and Hypotheses
1.4.1 Project 1
Three fabrication methods were used to dope methotrexate with HNTs. By 
comparing the loading and release results, we may be able to identify the impact o f 
loading and release processes, such as the pH, temperature, concentration, spatial 
structure, polyelectrolytes, etc. In this way, information on the loading and release 
processes with the HNTs based drug delivery system may be used to improve the 
delivery system.
1.4.2 Project 2
In the first in vitro test, osteosarcoma cells were used as the disease model, 
because metastasis and recurrence are still the most common causes leading to patient
death after surgical remove o f the primary tumor mass. MTX is a commonly used drug in
the treatment o f  osteosarcoma and was used as the model drug for delivery. MTX was 
supposed to be loaded within the HNTs based drug delivery system, and could be 
released subsequently in a sustained manner. Besides, released MTX could keep its 
biological function intact during the whole process, and act on the osteosarcoma cells. In 
this way, the HNTs based drug delivery system showed a potential to deliver
4chemotherapeutics to target sites o f the tumor to prevent postoperative metastasis and/or 
recurrence.
1.4.3 Project 3
In the second in vitro test, surgical site infection was the targeted disease model, 
as it is a common complication in surgery. It causes unnecessary direct health problems 
and indirect social cost to patients, and increases the financial burden on society. 
Nitrofurantoin was selected as the model drug, and E. coli was used as the target 
pathogen. NFT was supposed to be loaded within the HNTs based drug delivery system, 
and could be released in a sustained manner in bacterial broth with its biological function 
intact. Then, it could subsequently act on the bacteria and inhibit its growth. The same 
result should be achieved when NFT coated HNTs were filled within nylon - 6  which is a 
routine material for sutures. In this way, antibiotics could be delivered to the surgical site 
and be released locally to prevent the potential infection.
1.5 Exclusions
In this dissertation, all o f  the work was focused on passive drug delivery. Active 
drug delivery is more complicated and would become the next step if  results from 
preliminary experiment are satisfied.
1.6 Outline of Dissertation
Chapter 1 introduces the objective and general background for this dissertation. It 
also describes the specific projects and associated hypotheses which will be discussed in 
subsequent chapters, and presents the organization o f this dissertation.
5Chapter 2 gives a brief literature review concerning the main concepts and 
technologies related to this dissertation: nanotechnology, drug delivery, halloysite 
nanotubes, layer-by-layer technique, osteosarcoma, and surgical site infection.
Chapter 3 describes the methods and instruments used in the experiment.
Chapter 4 introduces current fabrication methods which can be applied to prepare 
the HNTs based drug delivery system. By comparing the loading and release results, 
factors which may affect the loading and release process were discussed, such as pH, 
concentration, spatial structure, and polyelectrolytes. Besides, advantages and limitations 
were compared among the studied fabrication methods, and the appropriate method could 
be selected for subsequent projects.
Chapter 5 presents the application o f using HNTs based drug delivery system to 
deliver MTX to osteosarcoma cells in vitro showing its potential in the treatment o f 
postoperative recurrence.
Chapter 6  describes the application o f using HNTs based drug delivery system to 
deliver NFT to E. coli in vitro showing its potential to prevent postoperative surgical site 
infection.
Chapter 7 concludes the results o f the dissertation, and recommends direction for 
future study.
CHAPTER 2
LITERATURE REVIEW
2.1 Nanomedicine
2.1.1 Nanotechnology and Medicine
The emerging trends and development o f nanotechnology have been attracting 
more and more attention, especially in medical fields. A specific term called 
nanomedicine is used to describe the application o f nanotechnology in medicine. There 
have been many promising applications o f nanomedicine including, but not limited to, 
drug delivery, in vitro diagnosis, in vivo imaging, therapy techniques, biomaterials, and 
tissue engineering, which are summarized in Table 2-1 [4], Some o f them have been 
realized and their products have entered the marketplace, while others are still under 
active research. Experts estimated that the global market o f nanotechnology-based 
products in medical fields would grow to $ 70-160 billion by 2015 [5-6],
Table 2-1: Nanoscale application in medicine [4].
Submedical
Field
Application
Drug Delivery
Nanotechnology based drug delivery systems can (1) enhance 
the therapeutic efficacy and minimize adversities associated 
with available drugs; (2) enable new classes o f  therapeutics; 
and (3) encourage the re-investigation o f pharmaceutically 
suboptimal but biologically active new molecular entities that 
were previously considered undeveloped.
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7In Vitro 
Diagnostics
Nanoscale sensors (e.g., nanowires, nanotubes, nanoparticles, 
cantilevers, and micro/nanoarrays) can enable fast and high 
throughput detection o f disease biomarkers with higher 
sensitivity and lower sample consumption. Nanotechnology 
also offers hope for the early detection o f  viruses, bacteria, and 
circulating tumor cells, as well as for single cell analysis.
In Vivo 
Imaging
Targeted imaging nanoprobes (e.g., magnetic nanoparticles, 
quantum dots, and carbon nanotubes) could provide a faster, 
less invasive, and more accurate way to diagnose diseases 
(e.g., cancer) at their earliest stages and monitor disease 
progression. Some other possible opportunities include 
reporting in vivo efficacy o f therapeutics and tracking 
nanocarrier biodistribution in the body. In addition, imaging 
nanoprobes could help surgeons to locate tumors and their 
margins, identify important adjacent structures, and map 
sentinel lymph nodes.
Therapy
Techniques
Certain nanomaterials have unique therapeutic properties that 
differ from conventional drugs, and can, therefore, be directly 
used to treat diseases. For example, hafnium oxide- and gold- 
based nanoparticles can greatly enhance X-ray therapy; gold 
nanoshells/nanorods carbon nanotubes, magnetic nanoparticles 
can induce hypothermia to kill cancer cells; and 
nanocrystalline silver is being used as an antimicrobial agent.
Biomaterials
Biocompatible nanomaterials that have optimal mechanical 
properties can be used as medical implants, such as dental 
restoratives and bone substitutes (also categorized as hard- 
tissue engineering.). Nanocoatings or nanostructured surfaces 
can also improve the biocompatibility and adhesion o f 
biomaterials.
Tissue
Engineering
Nanotechnology can enable the design and fabrication o f 
biocompatible scaffolds at the nanoscale and control the 
spatiotemporal release o f biological factors, resembling native 
extracellular matrix, to direct cell behaviors, and eventually 
lead to the creation o f  implantable tissues.
2.1.2 Nanotechnology and Drug Development
Drug discovery and development is one o f the many fields in medicine that 
benefit from nanotechnology. In the pharmaceutical industry, an ideal candidate o f  new
8molecular entity (NME) for potential drug development should demonstrate potent 
biological activity, appropriate water solubility, and enough circulating half-life.
Actually, some NMEs have adequate bioactivity but show poor water solubility or short 
half-life period in circulation, while others have good solubility and half-life period but 
weak biological function. In either case, there is always a degree o f  compromise, and the 
drug developmental potential is less ideal than expected. Fortunately, breakthroughs in 
nanotechnology make it possible to address some o f these shortcomings associated with 
potential NMEs. For example, nanotechnology can significantly improve the 
pharmacological properties (like water solubility and circulating half-life in blood) o f 
such NMEs, leading to the discovery o f optimally safe and effective drug candidates [4]. 
In this way, nanotechnology could revolutionize the rules and possibilities o f developing 
new drugs. In fact, many current nanotechnology-based therapeutic products have been 
validated through the improvement o f previously approved drugs, and some novel classes 
o f nano-therapeutics are now underway [7-9].
2.2 Drug Delivery
2.2.1 Nanomaterials for Drug Delivery
Nowadays, more and more papers are published every day about drug delivery 
based on nanomaterials that show an increasing attention to the research o f 
nanomaterials. Obviously, nanomaterials offer many advantages (Table 2-2) as drug 
delivery vehicles. Drug particles are expected to go through a long route inside the 
human body to reach scheduled sites and act on targeted tissues and cells. However, there 
are some physiological hindrances that may greatly decrease the drug efficacy and create 
the need for using nanomaterials to assist in the delivery o f  scheduled drugs. Therefore,
9first, nanoparticles must have suitable dimensions that allow them to smoothly pass tiny 
capillaries with 5-6 microns in diameter. A range o f 10-100 nm is required for particles to 
proceed through systemic circulation [5]. Then access to various sites inside the body is 
available. Secondly, nanoparticles are more easily consumed by cells via internalization 
than larger micromolecules, which can help increase drug efficacy. The integrated drug 
could be released from the nanoparticles and act more efficiently inside the cytoplasm. 
Thirdly, nanoparticles have the potential to be used for targeted drug delivery at the 
specific disease area, improving drug efficiency. Fourthly, the controlled release o f drugs 
from nanoparticles can help lessen undesired side reactions. Therefore, nanomaterials 
hold great potential for the improvement o f  the overall therapeutic index, offering another 
option for drug delivery.
Table 2-2: Advantages o f  nanomaterials in drug delivery.
Advantages
(1) Ability to pass through narrow capillaries and accessibility o f remote 
areas
(2) Easily consumed
(3) Delivery at specific diseased area via active or passive targeting
(4) Controlled release
In fact, there has been a long history o f  applying nanotechnology in drug delivery. 
Since liposomes were first introduced as carriers for drugs and proteins in 1960 [6], 
nanotechnology has entered the field o f  nanomedicine, and there have been many 
nanotech-based products approved by the FDA or still in clinical trials (Figure 2-1) [7-9].
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Figure 2-1: Timeline o f nanotechnology-based drug delivery systems. Here, we 
highlight some delivery systems that serve as important milestones throughout the 
history o f drug delivery. Adapted from “Nanotechnology in Drug Delivery and Tissue 
Engineering: From Discovery to Applications” by Jinjun Shi, et al, 2010, Nano Letters, 
10(9), p. 3223-3230.
The main purposes o f  using nanotechnology in drug delivery applications are (1) 
to improve the delivery o f water insoluble drugs [7]; (2) to deliver large macromolecule 
drugs into intracellular sites o f action; (3) to co-deliver two or more drugs or therapeutic 
agents for combination treatment; (4) to transport drugs across tight epithelial and 
endothelial barriers [8]; (5) targeted delivery o f drugs in a cell- or tissue-specific manner; 
(6) real-time read on the in vivo efficacy o f  a therapeutic agent, and (7) visualization o f 
sites o f drug delivery by combining therapeutic agents with imaging probes [9],
2.2.2 Classification o f Drug Delivery
According to the mechanism o f how the drugs are delivered to action sites, drug 
delivery can be classified as two types: passive and active delivery (Table 2-3).
Table 2-3: Drug delivery: passive targeting versus active targeting [10].
Passive Targeting Active Targeting
(1)
Utilizes special deviated 
conditions prevailing in the 
diseased area
Depends on targeting ligands and 
corresponding biomarkers that are 
overexpressed in diseased cells or 
tissues
(2) Less selective Highly selective
(3) Restricted in use Very versatile
(4) More likely to produce side 
effects
Less likely to induce side effects
Passive delivery facilitates the deposition o f nanoparticles incorporated with 
drugs in their action sites by taking advantage o f  certain biophysical properties. The most 
common examples are direct drug injection and catheterization. Spontaneous drug 
accumulation in a diseased area with leaky vasculature is another form o f passive 
delivery. This approach is based on the preparation o f a drug carrier complex that can 
avoid removal through the body mechanisms (like metabolism, excretion, opsonisation, 
and phagocytosis) and stay in the blood circulation allowing its transmission to targeted 
disease areas. An important application o f this mechanism is the delivery o f 
chemotherapeutics in the treatment o f cancer, where a special phenomenon called 
enhanced permeability and retention (EPR) could be well utilized. In oncology, there are 
some unique structural features shared by many solid tumors, including hypervasculature, 
defective vascular architecture, and impaired lymphatic drainage leading to the well- 
characterized EPR effect [10]. These distinctive characteristics are inherent to the tumor 
milieu, but are not normally present in healthy tissues [11]. Besides, properties o f the 
nanoparticles which include molecular size, shape, and surface charge could also affect 
the delivery. [11]. For example, previous studies have confirmed that macromolecules
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with a molecular weight higher than the renal threshold (40 kDa) tend to accumulate 
preferentially in neoplastic tissues upon intravenous administration [17-18]. The normal 
vasculature endowed with tight junctions is impermeable to molecules sized over 2-4 nm, 
and can keep the nanoparticles within the circulation; however, the leaky vasculature o f 
neoplastic tissue allows macromolecules with a diameter under 600 nm to extravasate 
into the neoplastic tissues [12]. Additionally, most tumors only have a poorly-developed 
lymphatic system, which would help these extravasated nanoparticles stagnate within the 
neoplastic tissue [20-21], Another example comes from the surface property. 
Nanoparticles coated with polyethylene glycol (PEG) and sized between 200 nm and 500 
nm could slip through a barrier o f  human mucus lining organs such as lungs, 
gastrointestinal tract, and cervicovaginal tract [5]. In this way, it is possible to deliver 
chemotherapeutics to tumors within the aforementioned organs.
Different from the passive approach, active delivery uses targeting ligands that 
can interact with some degree o f exclusivity with specific biomarkers overexpressed on 
targeted cells or tissues. These common ligands include sugars, folic acid, peptides, and 
explicitly engineered antibodies [5], They are connected with the drug loaded 
nanoparticles and direct them to targets in the body such as receptors, lipids, antigens, 
and proteins. For example, in M iao’s study [13], functionalizing hydroxypropyl-b- 
cyclodextrin copolymer nanoparticles were developed for targeting delivery o f  paclitaxel 
to integrin dy^-rich  tumor cells. In another study, Tomoki Sugiyama et al [14] used 
VEGFR (vascular endothelial growth factor receptor)-1-targeted peptide APRPG and 
integrin a v[T-targeted peptide GRGDS to decorate liposomes synergistically and tested 
them on proliferative HUVECs (human umbilical vein endothelial cells). Results showed
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that these dual-targeting liposomes could highly accumulate in tumor tissues o f tumor- 
bearing mice, and intratumoral distribution study indicated that they could also localize 
on angiogenic vessels as well as distribute around these vessels. Although more 
complicated than the passive approach, active delivery offers the widest opportunities and 
alternatives.
2.2.3 Current Status and Challenges
Ideally, a drug administered should reach the diseased site in the human body 
without affecting the healthy tissues and organs en route. After reaching the target, it can 
release the ingredients at the scheduled time in the appropriate dosage to heal. Further, 
after the diseased part is cured, the remnant drug could be expelled from the body to 
avoid any side effects. Especially in the treatment o f cancer, drugs with high efficacy and 
little side effect are always the first-line option. Additional delivery vehicles are 
developed to help achieve that ideal goal. For example, some common nanosystems 
include liposomes [24-26], polymeric micelles [27-30], polymer-drug conjugates [ 15], 
and dendrimers [16]. There are also some newer types developed or still under research, 
which include nanocages, nanogels, nanofibers, nanoshells, nanorods, and nanocontainers 
[5],
However, there is still a long way to go from the current nanoproducts to the 
ideally expected one. The translation o f  active delivery from laboratory to clinical 
application is not as smooth as people expect. One possible reason is the complicated 
manufacturing process, which includes biomaterial assembly, ligand coupling/insertion, 
and purification [4]. Another one is targeting ligands. Besides, there are some other 
considerable variables, such as ligand biocompatibility, cell specificity, binding affinity,
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mass production, purity, ligand surface density and arrangement, spacer type and length 
dividing ligand molecules and nanoparticles [33-34], In fact, o f  the current 
nanotechnology-based drug delivery systems that are in the market or still under clinical 
trials, the majority are passive delivery. Obviously, compared to the active approach, it is 
relatively simple and the requirement is not that harsh. The drug loaded nanosvstems 
would accumulate at the diseased area by utilizing unique characteristics inherent to the 
disease. Therefore, a thorough understanding o f  biological features is necessary for 
designing and preparing drug loaded nanosystems.
In this dissertation, an HNT based drug delivery nanosystem was built using the 
passive approach. The specific expected result o f using this tool was based on some 
characteristics o f biological environment inherent to the disease. In other words, the 
biological characteristics o f  the diseased area were utilized to enhance the efficacy as 
well as to reduce side effects o f the scheduled drugs, leading to improvement o f  the 
overall therapeutic result.
2.3 Halloysite Nanotubes
2.3.1 General Information and Structure
Halloysite nanotubes (HNTs) are naturally occurred alumino-silicate clay, and can 
be mined from natural deposits in many countries like America, Brazil, China, France, 
South Korea and Turkey [17]. They have a chemically similar composition as kaolinite 
Al2 Si2 0 5 (0 H)-4 nH 2 0  but with a difference being they have a hollow tubular structure. 
HNTs are formed by multiple bilayers o f  silicon dioxide and aluminum oxide. Most 
commercially available HNTs share a typical three-dimension structure: the inner 
diameter is between 10 and 20 nm, the external diameter ranges from 50 to 100 nm, and
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the length o f these tubes varies from 500 to 2000 nm [18]. Their wall is composed o f 10 
to 15 bilayers o f  aluminum and silicon oxide [ 18]. These structural features render 
halloysite a potential for drug delivery.
2.3.2 Current Application
Recently, halloysite nanotubes have attracted more and more researchers’ 
attention, and many papers have been published to report their achievements. In 
Ravindra’s review paper [19], some advantages o f applying halloysite nanotubes were 
pointed out, such as (1) natural, nontoxic, biocompatible; (2) fine particle size, high 
surface area and superb dispersion; (3) high cation exchange capacity; (4) maintains 
uniform, sustained release rates and no initial overdose; (5) capable o f  prohibiting release 
unless triggered and tunable release rates; (6) protects active agent within its lumen 
during harsh material processing; (7) capable o f loading multiple active agents 
simultaneously; (8) reduces the volume o f costly active agents; (9) implementable in 
many forms such as powders, creams, gels, lotions and sprays; (10) high aspect ratio, 
high porosity and non-swelling; (11) superior loading rates to other carriers, fast 
adsorption rate and high adsorption capacity; (12) regeneration ability and increased 
efficacy. Because o f these versatile properties, HNTs can be used in many biological and 
non-biological applications. In another paper, Rawtani and Agrawal [20] introduced 
multifarious applications o f halloysite nanotubes, like corrosion prevention, thermal 
resistance, fillers for various nanocomposites, cellular response, polymerization reactions, 
drug delivery, immobilization matrixes, and remediation.
In this dissertation, we will explore the potential o f HNTs in the field o f  drug 
delivery.
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2.4 Layer-by-Layer Assembly
2.4.1 Definition and Developmental History
Layer-by-layer (LbL) assembly is defined as the use o f oppositely charged 
materials with wash steps on a charged surface to build controlled architecture o f a 
multilayer polymer film (Figure 2-2).
Figure 2-2: An example o f layer-by-layer process through immersion.
This can be accomplished by using many techniques such as immersion, spin, 
spray, electromagnetism, or fluidics as reviewed by Richardson et al [21 ]. The first 
implementation o f this technique is attributed to Kirkland and Her, who carried it out 
using microparticles in 1966 [22], Later this method was revitalized by Gero Decher 
because o f the discovery o f its applicability to a wide range o f polyelectrolytes (PEs)
Activated 
Substrate (S) Repeated
IS Multilayer
AssemblyPolyelectrolyte I Washing Polyelectrolyte II
Solution
[23].
17
2.4.2 Mechanism
By definition, one may believe LbL multilayer build-up results solely from 
electrostatic attraction. Actually, many other attractive forces are also involved 
cooperatively; this is typical for high-molecular weight building blocks, while 
electrostatic repulsion provides self-limitation o f the absorption o f individual layers. This 
involvement and interactions o f multiple forces make it possible to extend the LbL 
technique to similarly charged polymers, hydrogen-bonded films [24], nanoparticles [25], 
hydrophobic solvents [26], and other unusual systems [27], With improvement in 
techniques, the deposition and wash steps can be performed in many different ways 
including dip coating, spin-coating, spray-coating, flow based and electro-magnetic 
techniques [21 ].The methods used to prepare the multilayer can distinctly impact the 
properties o f the products and allow their applications in various fields.
2.4.3 Advantages and Applications
The LbL technique offers several advantages over other thin film deposition 
methods, such as (1) the process is simple and can be inexpensive; (2) a wide range o f 
materials like polyions, metals, ceramics, nanoparticles, and biological molecules can be 
applied in LbL; (3) a high degree o f  control over the structure and thickness o f the 
multilayer films; (4) a resolution o f  1 nm by the fact that each bilayer can be as thin as 1
nm. Because o f  these properties, LbL has been used in many applications [21] including
corrosion control, biomedical applications [28], ultrastrong materials [29], and many 
more [30],
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2.5 Osteosarcoma
2.5.1 Epidemiology
It is estimated by the American Cancer Society that there are about 800 new cases 
o f osteosarcoma every year in the United States. However, osteosarcoma is the most 
common primary malignancy o f  bone in children and adolescents [31 ]. It usually occurs 
in the metaphysis o f  long bones like the distal femur, proximal tibia, and proximal 
humerus during the second decade o f life. Another small peak lies in between 60 to 80 
years [32]. Overall, it has a moderate incidence rate, with 10 to 26 new cases per million 
worldwide each year [33].
2.5.2 Treatment and Prognosis
Since first being introduced by Boyer in 1805 [34], osteosarcoma has been 
recognized for more than 200 years. However, the progress in prevention, diagnosis, and 
treatment o f this tumor is still very limited. It is pointed out by the American Cancer 
Society that there is no way to protect against osteosarcoma, and there are no special tests 
to find this tumor in people without symptoms or strong risk factors. The best way is to 
come to a doctor when any symptom o f this disease is noticed. W hat’s worse, pulmonary 
micrometastasis could occur in at least 80% o f patients at diagnosis [35], These 
metastases could not be found through conventional image tests. They can continue their 
growth and spread 8 to 12 months after the surgical removal o f the primary tumor mass, 
and become the main cause o f patients’ death within 12 to 24 months o f  their appearance 
[35]. The current standard treatment options include surgery, chemotherapy, and 
radiation. Surgical intervention can remove all the detectable tumor mass, while 
chemotherapeutics can kill the invisible micrometastasis around the whole body.
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Radiation is applied when patients cannot bear the severe side reactions o f the surgery 
and chemotherapeutics. In most cases, an effective treatment result requires the 
combination o f both surgery and chemotherapeutics.
2.5.3 Current Challenge and Novel Approaches
The 5-year survival rate in osteosarcoma in the first half o f the 20lh century was 
less than 20% [36].These patients were treated mainly with limb amputation and most o f 
them died o f lung metastasis [37]. In the 1970s, the application o f multi- 
chemotherapeutics, together with the gradually improved surgical techniques, helped to 
improve the 5-year survival rate to around 60% in localized osteosarcoma (Figure 2-3) 
[31].
5-year overall survival (%)
80 
60 
40 
20 
0
1960s 1970s 1980s 1990s 2000s 
Figure 2-3: Five-year overall survival o f  localized osteosarcoma [31].
By contrast, the long-term survival o f patients with metastatic osteosarcoma still 
remains at 25-30% [56-58]. The main chemotherapeutic agents used for metastatic 
osteosarcoma have not changed much during the past decades [38]. Therefore, new 
chemotherapeutic agents, technologies, and strategies are urgently needed to improve the 
outcome o f  treatment for patients with osteosarcoma.
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2.6 Surgical Site Infection
2.6.1 Epidemiology
Surgical site infection (SSI) is a common healthcare-associated infection (HCA1), 
which is estimated to account for 16% o f the total HCAI [39], In the United States, 
approximately five million cases o f SSI occur every year, leading to an average o f 7.3 
extra days in the hospital, and over 1.6 billion dollars o f additional hospital charges [40]. 
Some studies showed that around 5% o f all surgical operations were carried out with 
complications o f infection in hospitals in developed countries [41 ]. The situation in 
developing countries is significantly worse, and some studies pointed out that the 
infection rate may be twenty times higher than that in developed countries [42]. In a 
word, SSI has become a serious cause o f  morbidity, emotional stress, and financial cost 
to the affected patients and health care institutions [43].
2.6.2 Prevention
A good understanding o f  the SSI can be o f great assistance while a full clinical 
assessment is required to identify risk factors followed by measures to modify these 
factors. The Department o f Health (2007) and NICE (2013) recommend some measures 
[39] as follows:
1) Patients should stop smoking at least four weeks before surgery.
2) Pre-operative showering to reduce bacterial load on the skin
3) Antibiotic prophylaxis
4) Hair removal when required
5) Blood glucose should be controlled below 11 mmol/L
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6) Body temperature should be maintained above 36 °C within the perioperative period 
to prevent vasoconstriction
7) Skin and hands preparation o f those present in the operating room
8) SSI surveillance should be completed.
In daily routine, the application o f antibiotics is an indispensable part of the 
treatment o f  SSI. Efficient agents with fewer side reactions are always needed. Compared 
to conventional treatment, new nanotechnology-based drug delivery systems may offer 
some other options to patients and physicians.
2.7 Surgical Sutures
Sutures are routinely used in surgeries for the fixation o f tissue. Since they are in 
direct contact with the wound, they have excellent potential to be used for local delivery 
o f active molecules or cells to improve wound healing. In one recent study, adipose- 
derived stem cells were filled into surgical sutures to secrete cytokines and promote 
wound healing [44]. In another paper, an anti-infective coating o f  surgical sutures were 
developed with a combination o f  antiseptics and fatty acids [45]. An in vitro study was 
carried out and the result showed that a sustained release was observed, and 
Staphylococcus aureus could be efficiently killed. However, there are limited papers 
about using sutures as a carrier to deliver active molecules and cells to target sites. Plenty 
o f room is left for research regarding effective use o f  sutures for drug delivery.
CHAPTER 3
M ETHODS AND INSTRUMENTATION FOR EXPERIMENTATION
AND ANALYSIS
3.1 Benchtop Vacuum Pump
Vacuum loading, as one method to be tested, was used to load drug molecules 
into halloysite nanotubes. Figure 3-1 shows the equipment required for the drug loading 
process. The drug solution was made at controlled concentration. Then halloysite powder 
was added into the solution, followed by full vortex to mix the suspension completely. 
After that, the suspension was placed under vacuum (-25 in Hg) for 30 minutes. Air 
bubbles were observed, which may suggest the solution with drug molecules was 
replenished inside the nanotubes. When no air bubbles come out, the process was stopped 
and the suspension was stirred completely. Then the vacuum loading was restarted. This 
process was repeated three times. The final suspension was centrifuged, and the 
supernatant was collected for absorbance measurement, by which the amount o f  loaded 
drug could be calculated indirectly. The sediment was air-dried at room temperature, and 
crushed into fine powder for later use.
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Figure 3-1: Vacuum pump and ja r for vacuum loading process.
3.2 Ultraviolet Visible Spectroscopy
Ultraviolet visible spectroscopy was used to measure the absorbance o f sample 
solution that contains target drug molecules. Figure 3-2 shows the Nanodrop 2000c that 
was used in the absorbance measurement. A standard calibration curve should be built 
first through measuring several absorbance values o f target solutions with known 
concentrations. Then a linear relationship could be built between the absorbance value 
and concentration o f drug solution. By comparison with the standard curve, the 
concentration o f the test solution can be calculated. This method was used in the release 
studies where the released methotrexate and nitrofurantoin from the HNTs based drug 
delivery system could be calculated.
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Figure 3-2: Nanodrop 2000c was used for UV-Vis absorbance measurement.
3.3 Scanning Electron Microscope 
Figure 3-3 shows the scanning electron microscope (SEM) Hitachi S-4800 used 
in this project. It uses an electron beam to collect sample information and form images. 
The electron beam is produced from an electron gun at the top o f  the microscope. It 
passes through the electromagnetic fields and lenses to focus on the sample. Once the 
sample receives the beam, it will emit X-rays and electrons that are collected by detectors 
as signals. These signals are then used to form images on the monitor screen. In this 
dissertation, the SEM was used to examine morphology o f halloysite nanotubes and 
halloysite/drug composites.
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Figure 3-3: Scanning electron microscope was used to image visual changes o f 
halloysite particles.
3.4 Inverted System Microscope 
Figure 3-4 shows the inverted microscope system o f Olympus 1X51 that was 
designed for practical convenience and cost-effective performance for live cell study, in 
vitro fertilization and other cellular injection applications. In this dissertation, a live/dead 
kit was used to test the cytotoxicity o f  halloysite-based composites to osteosarcoma cells. 
The Olympus 1X51 was used to record the cellular response on the exposure o f test 
nanoparticles.
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Figure 3-4: Inverted system microscope (OLYMPUS 1X51).
3.5 Microplate Reader LT-4000
Microplate readers are widely used in research, drug discovery, bioassay 
validation, quality control and manufacturing processes in the pharmaceutical and 
biotechnological industries and in academic organizations. In this dissertation, a kit called 
“CellTiter 96 Aqueous One Solution Reagent” (Invitrogen, Carlsbad, CA) was used to 
test the response o f osteosarcoma cells to the released methotrexate from the HNTs based 
drug delivery system. Figure 3-5 shows the microplate reader LT-4000 (Phenix Systems, 
La Jolla, CA) used to read the results.
Figure 3-5: Microplate reader LT-4000. A 96-well plate was used for the assay.
3.6 Thermo Scientific GENESYS 20
The Thermo Scientific GENESYS 20 (Houston, TX) (Figure 3-6) is a low-cost, 
easy-to-use, and reliable visible spectrophotometer designed for routine laboratories. In 
this dissertation, it was used to test the optical density (OD 600 nm) o f the test bacteria, 
which is directly related to cellular density. In this way, the effect o f the released drug 
could be indirectly reflected via the values.
Figure 3-6: Thermo Scientific GENESYS 20.
CHAPTER 4
FABRICATION M ETHODS OF LOADING HALLOYSITE  
NANOTUBES WITH DRUGS
4.1 Introduction
4.1.1 Background
Ideally, an agent should have content efficacy o f the desired biological function 
with few unexpected side effects. However, most currently available agents in the 
pharmaceutical market have more or less side effects, and their efficacy becomes lower 
and lower because o f  drug tolerance from long term use. Especially in the treatment o f 
cancer, which is still the most common cause o f mortality in humans, huge amounts o f 
chemotherapeutics are used to eliminate malignant cells. Meanwhile, normal cells and 
tissues are also attacked, and patients suffer from all kinds o f side effects, which can 
equally threaten their lives. Therefore, novel agents, technologies, and strategies are 
needed to improve medical treatment for patients.
4.1.2 Drug Delivery
It is currently estimated to take a decade and cost over 120 million dollars to bring
a new drug through discovery, clinical testing, development, and regulatory approval
[46]. Another strategy is to improve the safety and efficacy o f  current drugs by delivering 
drugs at a controlled rate, slow and targeted delivery. Compared to conventional drug 
administration methods, the newly formed and nanotechnology-based drug delivery
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systems have several advantages in their inherent ability to overcome solubility and 
stability issues, localize drug delivery, and diagnose via in vivo image [1 ]. Theoretically, 
these systems can improve the stability, absorption, and therapeutic concentration o f 
drugs within the target tissue. They can also provide a sustained or controlled release at 
the target site. In the pharmaceutical industry, the research on drug delivery has become a 
strategy tool to expand drug markets through repackaging classic drugs in new delivery 
technologies. It is estimated that about 13% o f the currently global pharmaceutical 
market is related to the sale o f products based on drug delivery systems [3].
According to the mechanism o f how drugs are sent to the target sites, drug 
delivery systems can be divided into two types, active and passive delivery. In the active 
approach, biorecognition molecules are attached to the surface o f the nanovehicles to 
target specific biomarkers overexpressed by cells or tissues. In the passive approach, the 
goal is to facilitate deposition o f  nanocarriers within target sites, where some distinctive 
characteristics are present only in the target sites rather than normally healthy tissues, 
fake cancer as an example, the phenomenon o f enhanced permeability and retention is 
utilized to facilitate deposition o f nanoparticles loaded with chemotherapeutics within the 
tumor microenvironment. Although active targeting delivery is an ultimately ideal model, 
its transmission from theory to practice and from laboratory to clinical practice did not 
occur as smoothly as people expected. Compared to passive delivery, the requirement for 
active targeting is more rigorous such as higher exclusivity and longer stability in the 
blood circulation. Therefore, most o f the currently available drug delivery systems belong 
to the passive category. In this project, HNTs based drug delivery systems were built via
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three different methods. These methods were compared through their performance in 
both loading and release processes.
4.1.3 Hallovsite Nanotubes
Halloysite is a naturally occurring alumino-silicate clay and can be mined from 
natural deposits in many countries such as America, Brazil, China, France, Japan, South 
Korea and Turkey [17]. It has a similar chemical composition with kaolin, but differs in 
having a hollow tubular structure. Most o f commercially available HNTs share a typical 
three dimension structure: the inner diameter is between 10 and 20 nm, the external 
diameter ranges from 50 to 100 nm, and the length o f these tubes varies from 500 to 2000 
nm [18]. Their wall is composed o f  10 to 15 bilayers o f  aluminum and silicon oxide [18]. 
They have a huge surface area around 65 m2/g and a big pore volume o f  1.25 ml/g [19], 
All o f  the above characteristics make HNTs a good alternative for drug delivery. In this 
chapter, we will discuss some common fabrication methods used for drug loading with 
HNTs, to show the potential o f using HNTs in drug delivery.
4.2 Materials and Methods
4.2.1 Materials
Halloysite nanoclay, methotrexate, sodium hydroxide solution (1 mol/1), 
hydrochloric acid solution, polyvinylpyrrolidone (Molecular W eight-1,3000,000; 1 
mg/ml in DI water), and poly(acrylic acid) solution ( Molecular W eight-250,000, 3 
ml/100 ml in DI water) were obtained from Sigma Aldrich, St. Louis MO.
4.2.2 Standard Calibration Curve and Light Sensitivity Test
As it is said in the product instruction that methotrexate (MTX) is sensitive to
light, the impact o f  light exposure on MTX needs to be examined first. A premade MTX
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solution with known concentration (1 mg/ml, pH=l 1) was kept without light protection in 
a regular laboratory environment. Samples o f the MTX solution were collected and 
measured by UV-Vis every 24 hours for one week. The values were compared with that 
o f  the original MTX solution, and results were analyzed with one-way ANOVA (IBM 
SPSS 22.0). To establish a standard calibration curve for the relationship between MTX 
concentration and absorbance value, several MTX solutions with different known 
concentrations were used. Then, the standard calibration curve for MTX was made from 
Excel.
4.2.3 Fabrication Methods
Three fabrication methods were used in this project, and they were physical 
adsorption, vacuum loading, and layer-by-layer (LbL) coating. The detailed process was 
described as follows.
4.2.3.1 Physical Adsorption
One hundred milligram HNTs powders were immersed into 1 ml MTX solution 
with controlled concentration at 1 mg/ml. A metal stir bar was added to keep stirring the 
suspension for 24 hours, which may help increase the contact between HNTs and M I X 
molecules. After that, the suspension was centrifuged and the supernatant was collected 
for UV-Vis absorbance measurement. The sediment was air-dried under regular room 
temperature, and was then crushed into fine powders for later use.
4.2.3.2 Vacuum Loading
One hundred milligram HNTs powders were immersed into 1 ml MTX solution 
with controlled concentration at 1 mg/ml. Then the suspension was placed into a ja r  that 
was connected with a vacuum pump. A metal stir bar was added to keep stirring the 
suspension while loading, which may help increase the contact between HNTs and MTX
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molecules. Once the negative pressure inside the ja r reached the pump limit (-25 in Hg), 
the vacuum pump was turned o ff and the ja r was sealed. After 24 hours, the ja r was 
opened and the suspension was centrifuged. The supernatant was collected for UV-Vis 
absorbance measurement, and the sediment was air-dried under regular room temperature 
as well as crushed into fine powders for later use. To avoid potential loss o f MTX 
molecules from HNTs, the wash step was not included. Theoretically, the HNT/MTX 
composite was a combinational result from physical adsorption and vacuum loading. 
Through comparison with the result o f physical adsorption, the pure amount o f MTX 
loaded inside the lumen o f HNTs could be indirectly obtained.
4.2.3.3 Laver-by-Laver Coating
As pH and the number o f coated bilayers o f polymers (PVP/PAA) may have an 
impact on the drug loading property, different pH (3, 5, and 7) with different numbers o f 
bilayers (3, 6, and 9) were used for LbL coating. To make the whole process simple, the 
HNT/polymer composite was premade first. One gram HNT powders were immersed into 
30 ml Polyvinylpyrrolidone (PVP) solution (0.1 mg/ml). Then the suspension was kept 
being shaken for 15 minutes and then centrifuged and the supernatant was removed. 
Deionized (DI) water was used to wash the sediment for 5 minutes, and was removed 
after centrifuge. The same procedure was repeated with poly(acrylic acid) (PAA) solution 
(0.1 mg/ml) to build the second layer. In this way, one bilayer was completed. The 
HNT/polymer composites were made according to the predetermined groups. Then, 100 
mg o f the HNT/polymer composites were immersed into 1 ml MTX solution with 
controlled concentration at 1 mg/ml and controlled pH correspondingly. All the
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supernatants were collected for UV-Vis absorbance measurement, and the sediments 
were air-dried and crushed into fine powders for later use.
4.2.4 SEM Scanning
The samples including HNTs, HNT/MTX composite, and HNT/polymers/MTX
composite were examined by SEM for any sign o f  visible change.
4.2.5 Drug Release Test
HNT/MTX or HNT/polymer/MTX composites (25 mg/sample) were immersed 
into 5 ml DI water, and the suspensions were placed on a shaker kept being shaken for 10 
minutes. Then the suspensions were centrifuged, the supernatants were collected for UV- 
Vis absorbance measurement, and 5 ml fresh DI water was replenished for continuous 
release. The process was repeated until only slight release o f  MTX could be detected in 
the supernatant. Then, sodium hydroxide water (pH=l 1) was used subsequently to trigger 
extra release.
4.3 Results and Discussion
4.3.1 Standard Calibration Curve
As the Nanodrop 2000c only has reliable accuracy when the absorbance value lies 
between 0 and 1, samples with high concentrations were approximately diluted before 
absorbance measurement. For the standard calibration curve, the results are shown in 
Table 4-1 and Figure 4-1. The linear relation between MTX concentration and 
absorbance value is strong and reliable within the absorbance value range between 0 and 
1, which can be used to calculate the concentrations o f MTX sample solutions.
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Table 4-1: Standard  ca lib ra tion  cu rve for M T X  (w aveleng th : 300 nm ).
Concentration
(ug/ml)
2 4 6 8 10 12 14 16 18 20
Absorbance
Value
.101 .203 .302 .401 .494 .586 .681 .774 .865 .956
Standard
Curve
y = 0.0 
concen
47x + 0.015 ( 
tration (ug/ml
I  = 0.999, y-absorbance va 
))
ue, x-MTX
Linear Relationship Between MTX Concentration and
Absorbance
y = 0.047x + 0.015 
R2 = 0.999|  0.8 
l o o
1  0.4 
<0,
0 5 10 15 20 25
Concentration (ug/ml)
Figure 4-1: Standard calibration curve for MTX made with Excel 2007.
4.3.2 Light Sensitivity Test o f MTX
Table 4-2 and Figure 4-2 show the results o f  the light sensitivity test o f MTX. 
SPSS (22.0) was applied to analyze whether a significant change occurred during a 7-day 
period o f light sensitivity test. A Shapiro-W ilk’s test (P>.05) showed that the UV-Vis 
absorbance values were approximately normally distributed for all o f the samples, and a 
Levene’s test verified the equality o f  variances in the samples (homogeneity o f variance)
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(P>.05). Then, the one-way ANOVA test (P>.05) showed that there was no significant 
difference among all these groups, which means the impact o f light exposure on the MTX 
could be ignored during a seven day period.
Table 4-2: Light sensitivity test for MTX (wavelength: 300 nm).
UV-Vis Absorbance Value
Day-1 Day-2 Day-3 Day-4 Day-5 Day-6 Day-7
Sample 1 .526 .532 .530 .529 .536 .542 .538
Sample 2 .535 .523 .523 .522 .532 .552 .542
Sample 3 .527 .516 .527 .532 .538 .523 .544
Mean .529 .524 .527 .528 .535 .539 .541
SD .005 .008 .004 .005 .003 .015 .003
P Value N/A .967 .993 1.000 .955 .678 .437
(1) One-way ANOVA (IBM SPSS 22.0) was used to analyze the statistical difference
among these data.
(2) SD stands for standard deviation.
(3) All the samples o f MTX solution were diluted 100 time fold.
P value shows the result comparison with Day-0.
Light Sensitivity Test for MTX
0.56
0.55
3  0.54
I  0.52 
1  0.51 
«  0.5 
0.49
0.53 mum
Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
Time Point
Figure 4-2: Result o f  light sensitivity test for MTX during a 7-day period.
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4.3.3 SEM Scanning o f HNT/MTX Composites
As we see in the SEM images (Figure 4-3), pure HNTs showed very smooth 
outside surfaces. The products from both physical adsorption and vacuum loading shared 
the same appearance as the arrow pointed in Figure 4-3 (B), and a bright layer could be 
seen on the outside o f  HNTs. In fact, in the process o f vacuum loading, MTX molecules 
could also be physically adsorbed to the wall o f  HNT. In other words, physical adsorption 
was partially included in vacuum loading. Figure 4-3 (C) and (D) show the images o f 
HNT/polymer composites from LbL fabrication, and a bright layer on the outside surface 
could also be seen. There is an obvious limit o f  the SEM that the differences in LbL 
structures with different numbers o f layers could not be observed, and they may present a 
similar appearance with the results from physical adsorption and vacuum loading. 
However, in Figure 4-3 (E) the uncoated portion o f  HNT was clearly seen as the arrow 
pointed, and the bright layer o f  LbL structure was also clearly pointed out in Figure 4-3
(F).
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Figure 4 -3 :  SE M  im a g es  o f  H N T s and H N T /M T X  c o m p o s ite s . ( A )  Pure H N T s p artic les; (B )  
M T X  attached  on  the o u ts id e  su rface  o f  H N T s; (C )  and (D )  sh o w  c lu m p ed  H N T /p o ly m er  
c o m p o s ite  from  L bL  fabrication ; (E )  and (F )  L bL  structure w a s  bu ilt on  th e  o u ts id e  su rface .
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4.3.4 Fabrication o f  HNT/MTX Composites
Three methods were used to fabricate the HNT/MTX composites, and they were 
physical adsorption, vacuum loading and LbL coating. A general statistical description o f 
the fabrication results is shown in Table 4-3.
Table 4-3: MTX loading within HNTs or HNTs/polymer composites.
H N T s/P o ly m er
(mg)
M T X  to  
lo a d ( u g )
M T X  load ed  
(u g )
E ffic ie n c y
(% )
P h y sica l A d sorp tion  (P A ) 1 0 0 4 0 .2 1 0 4 7 .6 5 3 0 .9 6 ± 3 .4 0 5 0 .7 0 4 0 .3 0
V acu u m  L o a d in g  (V L ) 1 0 0 ± 0 .2 1 0 4 7 .6 5 1 5 .2 8 ± l  1 .02 4 9 .2 0 4 1 .0 4
LbL
C o a tin g
pH = 3
3 b ila y ers  (3 —3 ) 1 0 0 ± 0 .2 1 0 46 .5 9 2 8 .5 5 4 4 .0 5 8 8 .7 3 4 0 .4 0
6  b ila y ers (3 —6 ) 1 0 0 4 0 .2 1 0 4 6 .5 9 7 9 .0 4 ± 0 .7 7 9 3 .5 3 4  0 .0 6
9  bi layers (3 —9 ) 1 0 0 ± 0 .2 1 0 46 .5 9 9 6 .7 7 4  0 .9 6 9 5 .2 3 4  0 .0 6
LbL
C o a tin g
pH = 5
3 b ila y ers ( 5 - 3 ) 1 0 0 4 0 .2 1 0 46 .5 7 5 2 .0 2 ± 2 .9 8 7 1 .9 0 4 0 .3 0
6  b ila y ers ( 5 - 6 ) 10 0 ± 0 .2 1 0 46 .5 7 8 9 .3 3 4 0 .8 9 7 5 .4 3 4  0 .0 6
9  b ila y ers (5 —9 ) 1 0 0 4 0 .2 1 0 46 .5 7 9 6 .4 2 4 2 .8 3 7 6 .1 0 4  0 .2 6
LbL
C o a tin g
p H = 7
3 b ila y ers (7 —3 ) 10 0 ± 0 .2 1 0 46 .5 4 7 6 .8 4 4 4 .3 7 4 5 .5 7 4  0 .4 2
6  b ila y ers (7 —6 ) 1 0 0 4 0 .2 1 0 46 .5 4 8 7 .0 6 4 1 0 .2 6 4 6 .5 7 4 1 .0 1
9  b ila y ers (7 —9 ) 10 0 ± 0 .2 1 0 46 .5 5 1 0 .6 0 4 3 .5 4 4 8 .8 0 4 0 .3 6
Instruction: 1. T h ere w ere  3 sa m p le s  in each  group .
In each test group, a certain amount o f MTX was successfully loaded within
HNTs or HNT/polymer composites. Groups o f physical adsorption and vacuum loading 
had a similar result, which was also close to the group o f LbL coated under pH 7, but 
significantly lower than those coated under pH 5 and pH 3. Among all the groups, the one 
coated with nine bilayers under pH 3 had the highest loading o f MTX, while the one with 
three bilayers under pH 7 was the lowest (Figure 4-4).
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MTX Loading Efficiency
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Figure 4-4: MTX loading efficiencies among all test groups.
As a nanocontainer, HNTs have a natural lumen which can be used to load small 
molecules. They also have a huge surface area o f 65 m /g and a big pore volume o f 1.25 
mL/g [19], and can physically adsorb molecules on the surface or trap them in the pores 
inside their structure. Therefore, a certain amount o f MTX could be adsorbed physically 
within HNTs.
The vacuum loading procedure used in this project was, in fact, a combination o f 
physical adsorption on the outside surface and vacuum loading inside the lumen. In 
practice, it is impossible to send MTX molecules into the lumen with no contact between 
MTX molecules and the outside surface o f  HNTs. Theoretically, the result o f  vacuum 
loading should be higher than that o f physical adsorption. However, the results in both
41
groups were almost the same. One possible explanation is the amount o f MTX loaded 
inside HNTs lumen could be statistically ignored. Or MTX molecules could not be 
loaded within the lumen.
The LbL structure built on the outside surface o f HNTs obviously increased the 
surface area and the porosity volume o f the nanoparticle, which can be utilized to attach 
more MTX molecules. As seen in the results, LbL structures with different numbers o f 
layers under different pH did impact the loading ability o f  MTX. It suggested that lower 
pH and more layers could help increase the capacity o f MTX loading. Still, statistical 
analysis is required to make a firm conclusion.
4.3.5 Statistical Characteristics o f Samples
Before the statistical comparison o f the three methods, it is necessary to figure out 
the impact o f LbL layers and pH on the HNTs’ fabrication within the LbL groups, and to 
select the best combination o f  LbL structure and pH. Table 4-4 shows the statistical 
analysis o f  the difference o f MTX loading with different numbers o f LbL layers when pH 
was controlled. The result o f MTX loading within the HNT/polymer composites was 
used as the parameter for comparison. A Shapiro-W ilk’s test (P>.05) showed that the 
results o f MTX loading were approximately normally distributed for all o f the samples, 
and a Levene’s test verified the equality o f variances in the samples (homogeneity o f 
variance) (P>.05). Then, one-way ANOVA with Post Hoc test was applied for the 
analysis (Table 4-4).
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Table 4-4: S tatistica l an a ly sis  o f  the im pact o f  LbL layers on M T X  loading.
pH=3 pH=5 pH =7
O ne-w ay A N O V A  
P Value
.000 .000 .002
Post Hoc Test within Each Groups
pH=3 pH=5 pH=7
3
bi layers
6
bilayers
9
bilayers
3
bilayers
6
bilayers
9
bilayers
3
bi layers
6
bilayers
9
bi layers
3
bi layers
N /A .000 .000 N/A .000 .000 N/A .232 .002
6
bi layers
.000 N /A .000 .000 N /A .027 .232 N/A .012
9
bi layers
.000 .000 N /A .000 .027 N /A .002 .012 N /A
In the groups o f pH 3 and pH 5, the number o f layers did play a role in the
performance o f  MTX loading. Given the results o f MTX loading in Table 4-3. a 
hypothesis could be made that more layers can help increase the MTX loading under pH 
o f 3 and 5. In the groups o f  pH 7, there was no statistical difference between groups o f 
three bilayers and six bilayers. However, both o f them were significantly different from 
groups o f  nine bilayers. Therefore, the trend that more layers could increase loaded MTX 
under pH 7 was not as strong as that under pH 3 and 5.
On the other hand, when the number o f  layers was controlled, the impact o f  pH on 
the MTX loading was shown in Table 4-5. Similarly, a Shapiro-W ilk’s test (P>.05) 
showed that the results o f MTX loading were approximately normally distributed for all 
o f the samples, and a Levene’s test verified the equality o f  variances in the samples 
(homogeneity o f  variance) (P>.05). Then, one-way ANOVA with Post Hoc test was 
applied for the analysis (Table 4-5).
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Table 4-5 : S ta tistica l ana lysis  o f  the im pact o f  pH  on M T X  loading .
3 bilayers 6 bi layers 9 bilayers
One-way ANOVA 
P Value
.000 .000 .000
Post Hoc Test within Each Groups
3 bilayers 6 bilayers 9 bilayers
pH 3 pH 5 pH 7 pH 3 pH 5 pH 7 pH 3 pH 5 pH 7
pH 3 N/A .000 .000 N/A .000 .000 N/A .000 .000
pH 5 .000 N/A .000 .000 N/A .000 .000 N/A .000
pH 7 .000 .000 N/A .000 .000 N/A .000 .000 N/A
Obviously, pH made a significant difference in each o f  the groups, which means 
lower pH helped increase MTX loading in all test LbL coating groups. Based on the 
above results, the group with nine bilayers under pH 3 had the highest MTX loading 
within the LbL coating groups, which was also much higher than both o f the groups o f 
physical adsorption and vacuum loading.
An independent samples test was done between the groups o f physical adsorption 
and vacuum loading, and there was no significant difference between them. Some 
possible explanations could be (1) the negative vacuum pressure (-25 in Hg in this 
project) might not be strong enough under laboratory conditions; (2) the molecular size o f 
MTX is bigger than the inner diameter o f HNTs lumen. When compared with the LbL 
coating fabrication, neither physical adsorption nor vacuum loading had a better 
performance in MTX loading.
4.3.6 Factors Affect the Drug Loading Process
In all o f the fabrication methods used in this project, no chemical reaction 
occurred between MTX and HNTs or HNT/polymer composites. HNTs have a natural
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tubular structure inside where small molecules could be stored. They also have a huge 
surface area and porosity volume that could be utilized to adsorb or trap target molecules. 
The LbL structure built on the outside surface can further increase the surface area and 
pore volume, which accounts for the higher capacity o f MTX loading. Theoretically, 
unlimited layers could be added continuously, which may suggest ideal capacity for drug 
loading. However, abundant clumps o f HNT/polymer composites (Figure 4-3 C and D) 
formed during the LbL coating process, and the number o f layers was greatly limited.
The pH could indirectly affect the capacity o f  MTX loading in HNT/polymer 
through its important role in the LbL structure. As seen in the polyelectrolyte pair o f  PVP 
and PAA, a lower pH could help increase the MTX loading.
Some other factors like the drug solubility, size, and charge also have some 
influence on the loading process with the HNTs based drug delivery system. Obviously, a 
higher concentration o f loading solution could have more MTX attached or trapped 
within HNTs or HNT/polymer composites when the final balance arrives.
4.3.7 Drug Release
As pH and the number o f  layers within the LbL structure play a role in the process 
o f MTX loading, groups o f  samples with LbL structure were compared among 
themselves. Figure 4-5, Figure 4-6, and Figure 4-7 show the results o f MTX release 
where pH was controlled to show the impact o f number o f  layers on the release.
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Figure 4-5: UV-Vis absorbance measurement result o f MTX release within groups 
where MTX was loaded under pH 3. DI water was used for the first six times, and 
sodium hydroxide (pH 11) was used for the rest.
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Figure 4-6: UV-Vis absorbance measurement result o f MTX release within groups 
where MTX was loaded under pH 5. DI water was used for the first six times, and 
sodium hydroxide (pH 11) was used for the rest.
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Figure 4-7: UV-Vis absorbance measurement result o f  MTX release within groups 
where MTX was loaded under pH 7. DI water was used for the first six times, and 
sodium hydroxide (pH 11) was used for the rest.
It is clear that when pH was controlled, the number o f LbL layers did not have a 
significant impact on the release profile. Within each pH group, the results looked the 
same. In all these groups, a burst release was seen the first time, and subsequent lower 
and lower releases continued until the second peak o f MTX release, where sodium 
hydroxide was used to trigger extra release.
Figure 4-8, Figure 4-9, and Figure 4-10 show the results o f MTX release where 
LbL structure was controlled to expose the impact o f pH on the MTX release profile.
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Figure 4-8: UV-Vis absorbance measurement result o f MTX release within groups 
where MTX was loaded with three bilayers o f (PVP/PAA). DI water was used for the 
first six times, and sodium hydroxide (pH 11) was used for the rest.
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Figure 4-9: UV-Vis absorbance measurement result o f MTX release within groups 
where MTX was loaded with six bilayers o f  (PVP/PAA). DI water was used for the 
first six times, and sodium hydroxide (pH 11) was used for the rest.
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MTX Release Within Groups o f 9 Bilayers
Release Time
Figure 4-10: UV-Vis absorbance measurement result o f  MTX release within groups 
where MTX was loaded with nine bilayers o f (PVP/PAA). DI water was used for the 
first six times, and sodium hydroxide (pH 11) was used for the rest.
Still, a burst release was seen the first time, and subsequent lower releases went 
on until the second peak where sodium hydroxide was used for extra MTX release. 
Although the shape o f the release profile in each group was the same, the groups o f  pH 3 
had the highest release almost every time while the groups o f pH 7 had the lowest. Unlike 
the number o f bilayers in the LbL structure, pH showed a significant impact on the 
release results, which suggests that a lower pH may help increase the release o f MTX.
Therefore, within the LbL coated HNTs groups, the one with nine bilayers under 
pH 3 was selected to represent the LbL coating fabrication for comparison with the other 
two methods. Figure 4-11 shows the results o f  MTX release among the three fabrication 
methods.
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Figure 4-11: UV-Vis absorbance measurement result o f MTX release among groups 
with different fabrication methods. DI water was used for the first six times, and 
sodium hydroxide (pH 11) was used for the rest.
Still, the shapes o f  the release profile were the same. However, the group with 
LbL structure had the highest release while the other two shared the same performance. 
Additionally, the ratio between test particles and water could also affect the release 
profile. In this project, the ratio was controlled at 5mg/ml, and the release process was 
repeated ten times.
4.3.8 Process o f Drug Release
The main factor that drives loaded MTX to be released in surrounding solution is 
the concentration gradient, which is also the same mechanism used in the drug loading 
process. All the dissolved MTX molecules keep moving around in the solution all the 
time. Some moved from HNTs to surrounding solution, while others moved from 
solution to HNTs, which means both the loading and releasing processes were occurring
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at the same time. However, the net moving direction o f the total molecules was consistent 
with the concentration gradient between the solution and the HNT/MTX nanoparticles. 
Once a new balance was reached, the net moving stopped. When fresh DI water was 
replaced, a new concentration gradient formed, and the net moving o f  MTX molecules 
towards a lower concentration restarted, which would continue until the next balance 
occurred.
The burst release o f MTX on the first time could be explained by the theory o f 
concentration gradient, as it had the biggest value on the first time. When sodium 
hydroxide was replenished instead o f DI water, all o f the test groups showed a second 
peak o f  release. The reason is the basic environment can increase the solubility o f  MTX 
in water, and increase the net movement o f MTX molecules from HNTs to solution. It 
well explains the second peak in the groups o f physical adsorption and vacuum loading.
In the groups o f LbL coating, not only did the higher pH increase the solubility o f 
MTX, it also changed the LbL structure leading to more MTX molecules releasing from 
HNTs. The best evidence is the superimposed release o f MTX in the LbL coating group, 
which was higher than that in both groups o f the others. Therefore, the LbL structure 
could help carry more MTX molecules than pure HNTs. In this style, the loaded MTX 
molecules would continuously be released into the surrounding environment, and the 
period for this release process would be partially determined by the rate o f MTX 
consumption by the circumambient tissue.
4.4 Conclusions
In this chapter, MTX was successfully loaded within HNTs or HNT/polymer 
composites through three methods including physical adsorption, vacuum loading, and
LbL. coating. HNTs coated with the LbL structure had a significantly higher ability than 
the other two methods in MTX loading, and there was no statistical difference between 
physical adsorption and vacuum loading in the performance o f MTX loading and 
releasing, which may suggest that little or slight MTX was loaded within the HNTs 
lumen. Although it has already been reported that HNTs could be used to load resveratrol 
within their lumen space [47], the same method was not well applied with MTX. pH had 
a very important role in the MTX loading, while the number o f coated layers could only 
slightly increase the loaded MTX under lower pH. In the release process, a burst release 
was seen in all the test groups, and subsequent lower releases continued until a second 
peak occurred by the usage o f sodium hydroxide. Compared with pure HNTs, the LbL 
coated HNTs had higher release o f MTX, which may show a potential o f longer release 
period. Besides the properties o f HNTs or HNT/polymer composites, the consumption 
rate o f MTX by the surrounding environment could partially determine the length o f the 
release period, too. As a natural nanomaterial, HNTs showed great potential o f loading 
and releasing target molecules, and offered another option for drug delivery.
CHAPTER 5
POTENTIAL APPLICATION OF USING HALLOYSITE  
NANOTUBES BASED DRUG DELIVERY IN THE  
TREATM ENT OF OSTEOSARCOM A
5.1 Introduction
This chapter is based on my published manuscript titled "Drug Coated Clay 
Nanoparticles fo r  Delivery o f  Chemotherapeutics, " Current Nanoscience, 2016, 12(2) 
[48]. 1 am the author o f this paper, and its content is used only in my dissertation. In this 
chapter, an in vitro cellular test with osteosarcoma is used to show the potential o f using 
HNTs as a tool to deliver chemotherapeutics in the treatment o f cancer.
5.1.1 Halloysite Nanotubes
Halloysite nanotubes (HNTs) are naturally formed alumino-silicate clay tubules 
that are chemically similar to kaolin clay [70-72]. HNTs occur abundantly in nature and 
can be readily mined and sorted, making them an economically viable nanomaterial [49]. 
HNTs are routinely used as a functional filler to improve the mechanical performance o f 
cements and polymers [74-76]. The geometrical structure and surface charges o f HNTs 
make the material a viable nanocontainer for drugs, bioactive macromolecules, and 
polymers, for sustained and extended releases [77-79].
Recently, a publication reported the application o f using HNTs to deliver 
resveratrol to cancer cells [47]. Their inner luminal space was used for loading resveratrol
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and an additional coating o f poly(sodium 4-styrene-sulfonate) and poly(allylamine 
hydrochloride), or protamine salt and dextransulfate sodium salt was coated on HNTs to 
slow the drug release. With a negatively charged outer surface, HNTs can be effectively 
coated by sequential adsorption o f  positively and negatively charged polyelectrolytes 
(layer-by-layer (LbL) nano-assembly). LbL nano-assembly o f multiple polyelectrolyte 
nano-films has been shown as a potential multifunctional carrier system for drugs, 
enzymes, and cells [80-82]. Recent studies have also shown that HNTs display non- 
cytotoxic effects on several cell types such as mesenchymal stem cells, 
fibrochondrocytes, osteoblasts and human dermal fibroblasts (up to concentrations o f .1 
mg/ml) [83-84], The biocompatible and drug release properties o f  HNTs make them an 
ideal candidate for new drug delivery systems.
5.1.2 Methotrexate
Methotrexate (MTX) is commonly used in the treatment o f cancer, autoimmune 
diseases, ectopic pregnancy, and for the induction o f medical abortions. Since being 
discovered in the early 1970s, MTX has become one o f  the four major classes of 
chemotherapeutic agents with established efficacy in the treatment o f  osteosarcoma [50] . 
MTX is an antimetabolite and antifolate drug that inhibits dihydrofolatereductase, an 
enzyme involved in cellular DNA synthesis. It is generally considered that a serum 
concentration o f MTX greater than 1,000 pmol/1 administered as an infusion over four to 
six hours is required for successful therapy [85-86].
5.1.3 Osteosarcoma
Osteosarcoma (OSA) is the most common malignancy o f bone in children and 
adolescents, and is characterized histologically by the production o f an extracellular
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osteoid-like matrix. It represents about 3.4% o f all childhood tumors and 56% of 
malignant bone tumors [51]. Standard treatments include adjuvant chemotherapy, 
radiotherapy, hormone or biological therapy, and if  OS A is refractory, surgical ablation o f 
the primary tumor is needed. Advancements in treatment modalities have led to increased 
rates of'lim b-sparing' surgeries, but patients are still threatened with the risk o f 
recurrence. Tumor recurrence is greater than 90% for the patients without clinically 
diagnosed metastasis who receive surgical resection o f the primary malignancy and do 
not continue with adjuvant chemotherapy [50]. Surgical abscission can remove all sites o f 
clinically detectable tumor mass physically and systemic chemotherapy can inhibit 
micrometastasis before and/or after surgery. Other patients with similar disease 
conditions who are administered chemotherapeutic agents alone will suffer a 100% 
probability o f local recurrence without surgical excision o f  the primary tumor [52]. 
Significant advances have been made in the treatment o f osteosarcoma over time; 
however, new treatment and prevention strategies are still needed.
In this chapter, we demonstrate that polyelectrolyte coated HNTs loaded with 
MTX can be easily fabricated and that MTX coated HNTs can be embedded into nylon-6. 
HNT nanocomposites were tested for their cytotoxic and anti-proliferative effects against 
osteosarcoma cells. HNT/MTX doped composites were shown to alter osteosarcoma cell 
morphology and behavior and inhibit cell proliferation. Data support the potential for 
using doped HNT/polymer composites as a delivery tool for chemotherapeutic agents 
capable o f  delivering a focal and sustained concentration o f drugs.
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5.2 Materials and Methods
5.2.1 Materials
Osteosarcoma cells (OC, UMR-106) were obtained from ATCC, Manassas, VA. 
Halloysite nanoclay, methotrexate, sodium hydroxide solution (1 mol/1), hydrochloric 
acid solution (pH=2), Polyvinylpyrrolidone (M olecular W eight-1,3000,000; 1 mg/ml in 
DI water), poly(acrylic acid) solution ( Molecular W eight-250,000, 3 m l/100 ml in DI 
water), nylon-6, and formic acid solution were obtained from Sigma Aldrich, St. Louis, 
MO. 96-well plates and other lab plastics were purchased from MidSci, St. Louis, MO. 
Dulbecco’s Phosphate Buffered Saline (DPBS), Dulbecco’s Modified Eagle's Medium 
(DMEM), fetal bovine serum (FBS), Live/Dead Viability/Cytotoxicity kit and penicillin- 
streptomycin-amphotericin (PSA) antibiotics were obtained from Life Technologies, 
Carlsbad, CA. CellTiter 96 Aqueous One solution reagent was purchased from Promega, 
Madison, WI.
5.2.2 Composite Fabrication
Two hundred milligram HNTs were immersed in 1 ml o f polyvinylpyrrolidone 
solution (1 mg/ml, pH=2) and mixed for ten minutes. The mixture was then centrifuged 
at 13.4 xlOOO R.P.M. for three minutes and the supernatant was removed. The process 
was repeated with poly-acrylic acid solution (1 mg/ml, pH=2) and the alternating o f  PVP 
and PAA was repeated. A total o f six layers were deposited (HNT/(PVP/PAA)3 ). After 
the sixth layer, 1 ml o f methotrexate solution (1000 pg/ml, pH=2) was added and mixed 
for ten minutes, and centrifuged. The composites were dried and crushed into fine 
powder for later use. To avoid any potential loss o f MTX, the coating process ceased 
after the drug layer was added. The final structure was HNT/(PVP/PAA)j/MTX (see
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Figure 5-1). The HNT/(PVP/PAA)3/MTX composites were also examined as a functional 
filler for nylon-6 . Nylon - 6  solution (20% w/w) was prepared by dissolving with formic 
acid. HNT/(PVP/PAA)3/MTX (3% w/w) was mixed into the nylon - 6  solution 
homogeneously, then poured into a 24-well plate, and was air-dried for 24 hours. The 
final product was nylon - 6  loaded with HNT/(PVP/PAA)3/MTX. Figure 5-1 details the 
coating architecture o f  control and experimental groups.
+  PVP
♦  PAA
• MTX HNTs HNTs/PVP
£
HNTs/PVP/PAA
= > « = >
HNTs/PVP/PAA/PVP H NTs/PVP/PAA/PV P/PAA HNTs/PVP/PAA/PVP/PAA/PVP
= >
HNTs/PVP/PAA/PVP/PAA/PVP/PAA HNTs/PVP/PAA/PVP/PAA/PVP/PAA/MTX
Figure 5-1: Graphic illustration depicting the assembly of the polyelectrolyte coatings and 
drug infusion process on the surface of a halloysite nanotube. The assembly process begins at 
top left with specific steps proceeding from left to right and top to bottom. The fabrication is 
based on electrostatic interactions between all materials (Halloysite nanotubes (HNTs), 
polyvinylpyrrolidone(PVP), Poly (acrylic acid) (PAA), methotrexate(MTX)). This graphic 
depicts the process and is not meant to suggest the final coating structure.
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5.2.3 Scanning Electron Microscopy
Coated HNT samples were coated with (PVP/PAA)3/MTX and imaged with a 
Hitachi Field Emission Scanning Electron Microscope. Demonstration o f the coated 
HNTs and surface features were observed.
5.2.4 Drug Release Tests
First, a calibration curve was created for MTX to compare with the drug elution 
profiles o f the HNT/(PVP/PAA)3/MTX composites. Three sample sets, each with 20 mg. 
o f HNT/(PVP/PAA)3 /MTX, were immersed in deionized water (1 ml, pH=7.0) and mixed 
for ten minutes. Samples were centrifuged and the supernatants were collected for UV- 
vis. analysis (Nanodrop 2000c, ABS wavelength 300 nm). Samples were replenished 
with fresh DI water and the process was repeated 15 more times (total time=160 
minutes).
5.2.5 Cell Culture
Osteosarcoma cells were plated in 25 cm tissue culture flasks, and incubated at 
37 °C under humidified 5% C 0 2 and 95% air in complete DMEM containing 10% FBS 
and 1% PSA. Subconfluent cells were passaged with 0.25% trypsin, collected by 
centrifugation, suspended in complete DMEM and cultured at a 3:1 split into 25 cm 2 
tissue culture flasks. These cultures were used for viability and proliferation tests.
5.2.6 Viability and Proliferation Tests
Subconfluent osteosarcoma cells were released with 0.25% trypsin, collected by 
centrifugation, re-suspended in complete DMEM, and seeded in a 96-well plate. After 24 
hours, culture wells were then washed with DPBS. The cells were next exposed to 
DMEM alone, DMEM/HNT, DMEM/HNT/(PVP/PAA)3,
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DMEM/HNT/(PVP/PAA)3 /MTX, DMEM/HNT/(PVP/PAA)3 /nylon, and 
DMEM/HNT/(PVP/PAA)3/MTX/nylon. The cell density was controlled at 10,000 per 
well. Other parameters included: HNT (2000 pg/ml), HNT/(PVP/PAA ) 3  (2000 pg/ml), 
HNT/(PVP/PAA)3/MTX (2000 pg/ml), HNT/(PVP/PAA)3/nylon (10 mg/ml), 
HNT/(PVP/PAA)3/MTX/nylon (10 mg/ml). After 72 hours, the Live/Dead 
viability/cytotoxicity kit was applied for viability test, and the CellTiter 96 aqueous 
solution reagent was applied for proliferation test.
5.3 Experimental Results
5.3.1 Drug Coating
Under SEM microscopy uncoated HNTs displayed a tubular structure with 
smooth surfaces while coated HNTs (+/- MTX) have a thin coating as seen in Figure 5-2. 
HNTs often stacked together, with small clusters and aggregated clumps that may have 
resulted due to the drying preparation step required for electron microscopy.
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Figure 5-2: Scanning electron microscopic images of uncoated HNTs (A) and HNTs that have 
been coated HNT/(PVP/PAA)3/MTXXB), (C), and (D). Coated HNTs are visible in Figure (B) 
and (C) (arrows). Clusters of coated HNTs were seen in figure (C) and larger aggregate clumps 
(D) were observed and may have formed during processing for SEM.
Visual confirmation that coated and drug coated HNTs were successfully mixed 
into nylon - 6  is clearly visible in Figure 5-3. There were noticeable changes in contrast 
and color o f the coated HNT/nylon composites after being air-dried overnight, the formic 
acid evaporated completely leaving only the complex o f HNT/(PVP/PAA)3/nyIon and 
HNT/(PVP/PAA)3/MTX/nylon (Figure 5-3). Compared to HNT/(PVP/PAA)3/nylon, the 
yellow color o f  the HNT/(PVP/PAA)3/MTX/nylon suggests that MTX had been released. 
Results from the Live/Dead cytotoxicity and cell proliferation tests support this 
observation.
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Figure 5-3: T im e -la p se  im a g es  o f  the a ir-dried  co a ted  H N T  c o m p o s ite s  (A , C ). 
H N T /(P V P /P A A )3 (w h ite  d is k s )  v s . (B , D ) H N T /(P V P /P A A )3/M T X  (y e l lo w is h  t in t) .N y lo n -6  
so lu tio n  (2 0 %  w /w )  w a s  treated  w ith  fo rm ic  a c id . H N T /(P V P & P A  A )3 and  
H N T /(P V P /P A A )3/M T X  (3%  w /w )  w ere  then  th o ro u g h ly  m ix ed  in to  th e  n y lo n -6 so lu t io n , then  
poured  in to  a 2 4 -w e ll  p la te , and air-dried  and  o b serv ed  a fter  a 2 4  h ours p eriod .
5.3.2 Drug Release from HNTs
During drug elution monitoring, the HNT/(PVP/PAA)3/MTX samples showed a 
burst release during the first 1 0  minutes and continued with a steady release that slowly 
decreased until a second release peak after 130 minutes, with MTX released at reduced
levels through 160 minutes (Figure 5-4). The first release may be from a layer o f  drugs 
positioned on the very outer surfaces o f the composites. The second burst release may be 
due to the pH o f the immersing solution, which can affect the degradation rate o f the PEs. 
Also, some o f the drug molecules may have seeped out from the porous PE structures. 
The release study was terminated after 160 minutes, as very little amount o f MTX was 
being released. D1 water, with a neutral pH, was used as the elution medium during the 
release test. MTX concentration gradient and the pH o f immersing solution are presumed 
to have determined the release profile o f MTX. Overall, the PE coatings appeared to have 
effectively trapped MTX.
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Figure 5-4: D ru g re le a se  for M T X  from  H N T /(P V P /P A A )j/M T X  in DI w ater  (pH  7 )  o v e r  160 
m in u tes. T h e  U V  a b sorb an ce  rep resen ts th e  con cen tration  o f  M T X  in the sa m p les . F igure A  
d isp la y s  th e  am ou n t o f  drug  re leased  at each  tim e p o in t. F igu re B  sh o w s  th e  cu m u la tiv e  re lea se  
o f  a ll th e  sa m p le s  by  tim e  point.
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5.3.3 Live/Dead Cytotoxicity
Osteosarcoma cells in monolayer culture proliferated and obtained confluence within 2-3 
days with little cell death observed (Figure 5-5 A-C). Osteosarcoma cells were also unaffected by 
the addition of HNTs (Figure 5-5 D-F). Cells proliferated and achieved confluence comparable to 
normal, untreated cells (compare Figure 5-5 B and C with Figure 5-5 E and F).
B
Figure 5-5: Cytotoxic response to HNTS. (A-C) Group 1 :Osteosarcoma cell cultures with no 
HNT addition. (D-F) Group 2: Osteosarcoma cells exposed to HNTs at a concentration of 2000 
ug/ml). A, D = Phase contrast, B,E = Live Dead assay showing live cells (green), C, F = Dead 
assay showing dead cells (red). The brown coloration in figure 5-5D is due the high 
concentration of HNTs. Bar = 200 microns.
Coated HNTs (without MTX, control Group 3), HNT/(PVP/PAA), coated nanoparticles 
could be seen clearly as particulate material (Figure 5-6 A). Although osteosarcoma cells were 
not as confluent as seen in groups 1 and 2 , the majority of the cells were observed growing and 
proliferating with few cell deaths (Figure 5-6 A-C). In MTX treated groups, the cellular response 
was very different (Figure 5-6 D-F). In group 4, osteosarcoma cells exposed to HNTs with a
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(PVP/PAA)VMTX coating showed a marked reduction in cell growth as compared to controls 
(Group 3). However, only a few dead cells were observed (Figure 5-6 F).
Figure 5-6: Cellular response to PE coated HNTs and HNTs coated with PEs and MTX. (A-C) 
Group 3: Osteosarcoma cells were exposed to HNT/(PVP/PAAh (2000 ug/ml). (D-F) Group 4: 
Osteosarcoma cells were exposed to HNT/(PVP/PAA)VMTX (2000 ug/ml). A, D = Phase 
contrast, B, E = Live/Dead assay showing live cells (green), C, F = Live/Dead assay showing 
dead cells (red). Bar = 200 microns.
When HNTs coated with (PVP/PAA ) 3  were embedded in nylon-6 , results also 
showed a low cytotoxic effect, as cells grew to confluence with little cell death (Figure 
5-7 A-C). In contrast, cells exposed to HNT/(PVP/PAA)3/MTX/nylon grew but 
proliferation was inhibited with only a few dead cells observed (Figure 5-7 D-F).
Figure 5-7: Cellular response to coated HNTs embedded in nylon. (A-C) Group 5: 
Osteosarcoma cells were exposed to HNT/(PVP&PAA)3/nylon (10 mg/ml)). (D-F) Group 6 : 
Osteosarcoma cell were exposed to HNTs/(PVP&PAA)3/MTX/nylon (10 mg/ml). A, D = 
Phase contrast, B, E = Live/Dead assay showing live cells (green), C, F = Live/Dead assay 
showing dead cells (red). Bar = 200 microns.
5.3.4 Cell Proliferation Assay
The result o f  the cell proliferation assay is shown in Table 5-1. The values o f 
Groups 1, 2 and 5 were very similar suggesting that HNTs and HNT/(PVP/PAA)3 /nylon 
did not provoke an anti-proliferative response. Groups 3, 4 and 6  showed a reduction in 
cell proliferation, which can be attributed to the degraded polyelectrolyte layers (in 
Groups 3 and 4) and MTX released from the drug coated HNTs composites (in Groups 4 
and 6 ).
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T able 5-1: Control and experimental groups and their coating architecture with results 
o f the cellular proliferation assays.
Group Treatment Value
Control (DMEM only) 0.290 ± 0.000
Group 1 Normal cells 1.987 ±0.074
Group 2 HNTs only 2.118 ± 0.154
Group 3 HNTs/(PVP&PAA ) 3 1.114 ±0.097
Group 4 HNTs/(PVP&PAA)3/MTX 0.924 ±0.103
Group 5 HNTs/(PVP&PAA)3/ny Ion- 6 1.895 ±0.288
Group 6 HNTs/(PVP&PAA)3 /MTX/nyIon - 6 1.162 ± 0 . 1 2 0
Sixteen samples were used in each o f  the group (except group 2 which has 14 cases as 
two outliers were removed) for the cellular proliferation tests. The absorbance value is 
directly related to the number o f viable cells.
As shown in Figure 5-8, when exposed to uncoated HNTs and coated HNTs (+/- 
MTX), cellular response among these groups was significantly different. Compared with 
the group o f normal cells, cell proliferation was higher in the group o f  HNTs and stayed 
the same in the group o f  HNT/(PVP/PAA)3 /nylon, whereas it became lower in the other 
groups. A significant reduction was shown in the group o f
HNT/(PVP/PAA)3 /MTX/nylon, and a further reduction was seen in both groups o f 
HNT/(PVP/PAA ) 3 and HNT/(PVP/PAA)3 /MTX. The result o f  statistical analysis is 
shown in T ab le 5-1. SPSS (22.0) was applied with one-way ANOVA, and the normality 
(P>.05) and homogeneity (P=.044) were checked. Significant differences (P=.000) were 
seen among the groups, and subsequent Post Hoc tests were used to show the specific 
difference among the groups (Table 5-2). Overall, the pattern in cell proliferation mirrors 
that observed in the cytotoxicity analyses.
67
Results o f  The Cellular Proliferation Assays
Figure 5-8: S ix teen  sa m p le s  w ere  u sed  in each  grou p  (e x c e p t  G roup  2 w h ich  h as 14 c a s e s  as  
tw o  o u tliers  w ere  rem o v ed ) for th e  ce llu la r  p ro liferation  te s ts . T h e  a b sorb an ce  v a lu e  is d irectly  
related  to  th e  num ber o f  v ia b le  c e lls . From  le ft to  right, the grou p s are: D M E M  C on tro l, G roup  
I (N o rm a l c e l ls ) ,  G roup  2 (H N T s) , G roup  3 (H N T /(P V P /P A A )3), G roup  4  
(H N T /(P V P /P A A )3/M T X ), G roup  5 (H N T /(P V P /P A A )3/n y lo n ) , and  G roup 6  
(H N T /(P V P /P A A )3/M T X /n y lo n ). S ta tistica l a n a ly s is  w a s a p p lied  w ith  IB M  S P S S  2 2 .0 , and the  
stars in d ica te  a s ig n ifica n t d ifferen ce  e x is ts  w h en  com p ared  w ith  G rou p  1.
Table 5-2: T em p la te  for in sertin g  tab les .
Comparison Significant Difference (P value)
Group 1 Vs. Group 2 P = .000
Group 1 Vs. Group 3 P = .000
Group 1 Vs. Group 4 P = .000
Group 1 Vs. Group 5 P = .803
Group 1 Vs. Group 6 P = .000
Group 3 Vs. Group 4 P = .409
Group 3 Vs. Group 5 P = .000
Group 4 Vs. Group 6 P = .000
Group 5 Vs. Group 6 P = .000
IBM SPSS (22.0) and one-way Ah OVA were used for the statistical analysis.
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5.4 Discussion
In previous papers, the luminal porosity o f HNTs has been estimated to be around
■y
0.25 ml/g, while the outside surface area o f  HNTs has been shown to be about 57 m /g 
[53]. It is apparent that the HNT lumen has space limits for drug loading. Attempts have 
been made to enlarge the HNT lumen to increase drug loading by acid etching, and while 
increases in drug loading capacity were observed, there are limits to how much drug may 
be loaded with this technique [54], The outer HNT surface provides significantly more 
potential surface area for drug loading, especially if  the surface has been modified or 
coatings have been applied onto (or around) the outer surface. In HNTs, silica is mainly 
distributed on the outer surfaces, whereas alumina is mainly positioned on the inner 
surface and edges o f the tubule. Upon exposure to water, the outer surface will have a 
negative charge over a wide range o f  pH (2—10), so at an appropriate pH above 2, 
halloysites’ negatively charged outer surface permits sequential adsorption o f  positive 
and negative charged polyelectrolytes [53].
When immersed in water, PVP is positively charged [55] and PAA is negatively 
charged [56]. Accordingly, we used the outer HNTs surface rather than the inner luminal 
space o f HNTs to load and release MTX using a scheme for coating HNTs with 
sequential layers o f  positively charged PVP and negatively charged PAA [57]. In this 
way, the PE coatings provide a means for controlling both the location o f the drug and 
the pattern o f drug release. The data showed high concentrations o f  MTX were absorbed 
during the coating process, as little MTX was discemable in the acidic loading solution 
(pH=2) after coating process. This supports the conclusion that the majority o f the MTX 
molecules had been attached to the PE layers or trapped within the pore spaces. The two
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different burst releases seen in the UV-vis release data, suggests that the PE layers may 
have become more porous during fabrication. The first burst release o f MTX may have 
come from the MTX molecules attached to the outside surface o f the clumped material. 
The second burst release might have occurred because o f slow degradation o f the PE 
layers, which liberated more MTX molecules subsequently. Another important factor to 
consider is the rate o f MTX that is consumed by the environment, which may affect the 
length o f  drug release.
Cytotoxicity assays showed that osteosarcoma cells proliferated in the presence o f 
untreated HNTs and few cells died even after exposure to a very high concentration o f 
HNTs (2 mg/ml). This is consistent with previous studies where halloysite nanotube 
exposure had little negative impact on cell growth or functionality [83-84]. Furthermore, 
HNTs coated with PVP and PAA which was further mixed within nylon - 6  
(HNT/(PVP/PAA)3/nylon) also showed little to no cytotoxic effect. In the other groups, 
HNT/(PVP/PAA)3, HNT/(PVP/PAA)3 /MTX, and HNT/(PVP/PAA)3 /MTX/nylon showed 
little cytotoxicity, with only a few dead cells observed with the Live/Dead cytotoxicity 
assay. However, their cellular proliferation was significantly reduced.
Statistical analysis showed that Group 2 (HNTs, P=.000), Group 3 
(HNT/(PVP/PAA)3, P =.000), Group 4 (HNT/(PVP/PAA)3/MTX, P =.000), and Group 6  
(HNT/(PVP/PAA)3/MTX/nylon, P =.000) are significantly different from Group 1 
(Normal cells), which means the cell proliferation was significantly higher in Group 2 
and reduced in Groups 3, 4, and 6 . In Group 2, it seems that HNTs had a stimulant effect 
on the cells, as the mean was higher than that in Group 1. Although there was no MTX in 
Group 3, the reduction o f  cell proliferation might be caused by the interaction between
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hydrolyzed polymers and amino acids in the medium which led to a subsequent failure o f 
cell proliferation. In Group 4, besides the effect o f  hydrolyzed polymers, the release o f 
MTX further reduced the cell proliferation, but did not kill the cells. As there was no 
difference between Groups 1 and 5 (P=.803) which means the composites of 
HNT/(PVP/PAA)3 /nylon had no effect on the cells, the reduction o f  cell proliferation in 
Group 6  could only be explained as the release o f  MTX. The same principle could be 
used to explain the difference between Groups 5 and 6  (P=.000). No difference was 
shown between Groups 3 and 4 (P=.409), as both hydrolyzed polymers and MTX could 
only stop cell proliferation but not kill them. Group 5 was significantly different from 
Group 3 (P=.000), because the nylon structure could well trap hydrolyzed polymers 
which prevent their interaction with amino acids inside the medium. But it could not 
completely restrain the release o f MTX into the medium, which caused a limited 
reduction o f  cell proliferation in Group 6  when compared with Group 4 (P=.000).
In sum, morphological observations, cytotoxicity and proliferation assays support 
the conclusion that MTX was released from HNT/(PVP/PAA)3 /MTX and 
HNT/(PVP/PAA)3/MTX/nylon composites and subsequently altered osteosarcoma cell 
morphology and inhibited cell proliferation, which provided support for its potential use 
as a drug delivery vehicle. Our drug releasing system offers other advantages, including 
carrying a higher drug load as compared with using a vacuum to load drugs into the HNT 
lumen. When drug doped HNTs are added to different polymers there is a point where 
addition o f  increased amounts o f doped HNTs (to increase drug load) decreases material 
properties (tensile resistance, adhesion, etc.) [94-95]. Our method has the potential to 
overcome this by placing the appropriate (required) drug-load on the surface o f the
71
HNT/PEs, thus offering no challenges to material properties. Preliminary experiments 
with MTX release from nylon - 6  are suggestive that this method o f drug incorporation 
may also be applied to other polymers.
Current studies are directed at refining the specific PE shell structure with the 
intent to increase/decrease the loading ability o f HNTs, speed up/down drug release, and 
enable doping with multiple drugs. As we have shown, chemotherapeutic drugs can be 
doped into HNT/polymer mixtures such as Nylon - 6  and still retain an anti-cancer cell 
effect. This offers much promise for the incorporation o f drug coated HNTs into a variety 
o f medical grade, biocompatible synthetic polymers and/or natural proteins for use in 
anti-infective, chemotherapeutic or histiogenic catheters, gauze, sponges, and sutures.
5.5 Conclusion
Halloysite nanotubes did not provoke a cytotoxic effect on osteosarcoma cells nor 
inhibit their proliferation ability up to a concentration o f 2000 ug/ml. Methotrexate was 
incorporated into a PE coating and was observed to be released from the coating. 
Released MTX resulted in altered cell behavior including morphological changes in 
osteosarcoma cells and a reduction in cell proliferation. After the MTX-coated HNTs 
were mixed with nylon-6 , the releasing ability o f  MTX was preserved, and the released 
MTX also altered osteosarcoma cell behavior and inhibited cell proliferation. As a 
nanocomposite drug delivery system, MTX coated HNTs show a potential for the 
delivery o f  antitumor drugs. While MTX was the drug used in this study, there is also a 
potential for the system to incorporate other drugs. The system also has the potential to 
insert drugs at different coating depths that may permit multiple, combinatorial or even 
sequential release depending on coating architecture and composition.
CHAPTER 6
POTENTIAL APPLICATION OF USING HALLOYSITE  
NANOTUBES BASED SUTURES IN THE PREVENTION  
OF SURGICAL SITES INFECTION
6.1 Introduction
In this chapter, another application was used to verify the feasibility o f using 
halloysite nanotubes (HNTs) based drug delivery system in the medical field. The 
hypothesis was that nitrofurantoin (NFT) coated halloysite composites could release the 
drug in a sustained manner and efficiently inhibit bacterial proliferation, which showed a 
potential in the prevention o f surgical site infection (SSI).
6.1.1 Surgical Site Infection
Surgical site infection is a postoperative complication feared in surgery, and can 
lead to considerable consequences for patients and high medical cost for society [96-97]. 
It is a common healthcare-associated infection (HCAI), and accounts for about 16% of 
the total HCAI [39], In the United States, approximately five million cases o f  SSI occur 
every year, leading to an average o f 7.3 extra days in hospital, and over 1. 6  billion dollars 
o f additional hospital charges [40]. A prospective study from Spain [58] showed that SSI 
happened to 9.02% o f the total people who underwent surgery. Their stays were 
prolonged by 14 days, and the excess hospital costs were $10,232 per patient. What is 
worse, health costs only accounted for 1 0 % o f overall costs, and there was an extra
72
73
$97,433 per person from indirect social costs. SSI has become a serious cause o f 
morbidity, emotional stress, and financial cost to the affected patients and health care 
institutions [43]. Appropriate strategies, technologies, and agents are needed to improve 
surgical treatment and save unnecessary direct health costs as well as indirect social 
costs.
6.1.2 Nitrofurantoin and Drug Delivery
One Italian study for epidemiology and microbiology o f  surgical wound 
infections included 676 patients with signs and symptoms indicative o f infections, and 
showed common pathogens that included S. aureus, P. aeruginosa, E. coli, S. 
epidermidis, and E. faecalis [59]. Nitrofurantoin (NFT) is an antibiotic which has been 
proven effective against many bacterial pathogens including E. coli, S. aureus, and E. 
faecalis [60]. Because o f  low rate o f resistance, more and more attention has been 
focused on NFT. NFT exerts greater effects on bacterial cells than mammalian cells, and 
the development o f resistance to its effects is low because o f  its involvement in many 
different processes important to bacterial cells. For example, acquired resistance in E. 
coli continues to be rare [60]. However, it also has some shortcomings, which seriously 
limit its usage. The peak blood concentration o f NFT following an oral dose o f 100 mg is 
less than 1 ug/ml, and tissue penetration is negligible. It can be metabolized by the liver 
rapidly, and is excreted mainly in urine. Therefore, it is used mostly in urinary tract 
infections. The application o f a newly formed HNTs based drug delivery system could 
potentially improve this situation. Given its low tissue penetration and broad antibacterial 
function in the pathogens related to surgical site infection, NTF was used as a model drug 
loaded in the HNTs system and showed potential against E. coli to prevent SSI.
74
6.1.3 Electrospun Nanofibers and Sutures
Because o f the rapid development o f nanoscience and nanotechnology over the 
past decades, there are many advances made not only in preparation and characterization 
o f  nanomaterials, but also in their functional applications [61]. One example is the 
application o f nanofibers, which have been widely studied in the biomedical field, 
including drug delivery. Their advantages are obvious, such as 1) drug loading is easy to 
implement via electrospinning process; 2 ) the high applied voltage used in the 
electrospinning process has negligible influence on drug activity; 3) they have high 
specific surface area and short diffusion passage length which give the nanofiber drug 
delivery system higher overall release rate than bulk materials; 4) the release profile can 
be finely controlled by modulation o f nanofiber morphology, porosity and composition 
[61 ]. Therefore, electrospun nanofibers containing a HNTs based drug delivery system 
was used to form a scaffold, which could be potentially developed into sutures and 
widely used in surgeries. In this way, a local and sustained release o f antibiotics is 
expected to prevent potential SSI after surgery.
6.2 Materials and Methods
6.2.1 Materials
Halloysite nanoclay (H 4 Al2 0 9 Si2 -2 H2 0 , MW 294.19), Nitrofurantoin (C 8 H5N 4 O 5 , 
MW 238.16 g/mol), Sodium hydroxide solution (1 N), Hydrochloric acid solution (1 N), 
Polyvinylpyrrolidone ((C 6 H9NO)x, Molecular W eight-1,3000,000), Poly(acrylic acid) 
solution ( Molecular W eight-250,000, 35 wt.% in H 20), Nylon - 6  ((C6 HnNO)n, mp 220 
°C), LB Broth, and E. coli were obtained from Sigma Aldrich, St. Louis, MO.
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6.2.2 Light Sensitivity Test and Standard Calibration Curve
According to the product instruction, nitrofurantoin is sensitive to light, and the 
impact o f light exposure on NFT needs to be examined first. Saturated NFT solution was 
prepared, and its initial UV-Vis absorbance value was measured. Then, the solution was 
kept under routine laboratory conditions without light protection. Samples o f the NFT 
solution were collected and measured by UV-Vis every 24 hours. The results were 
analyzed with IBM SPSS 22.0 to find any significant change during the light exposure.
To establish a standard calibration curve for the relationship between NFT 
concentration and absorbance value, several NFT solutions with different known 
concentrations were used (Table 6-1). Then, the standard calibration curve for NFT was 
made through Excel (2007 Version).
6.2.3 Composite Fabrication
In Chapter 4, three common fabrication methods were compared, and the LbL 
coating was proven to be best in performance o f  both loading and releasing. Therefore, 
the LbL coating was used to prepare HNTs for NFT loading. Polyvinylpyrrolidone (PVP) 
and Poly(acrylic acid) (PAA) were used for the initial 18 layers o f  LbL coating on the 
outside surface o f HNTs. Then the FINT/polymer composites were air dried and crushed 
into fine powders. Next, 500 mg o f HNT/polymer composite was immersed into 5 ml 
acetone, which contains NFT at the concentration o f  4 mg/ml. A stir bar was used to keep 
stirring the suspension, which could help increase the contact between NFT and 
HNT/polymer composite. After 24 hours, the suspension was centrifuged, and the 
supernatant was removed. The sediment was air dried and crushed into fine powders for 
later use.
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6.2.4 Morphological Analysis: SEM
Pure HNTs and coated HNT/NFT composites were examined using a scanning 
electron microscope (Hitachi S-4800) to show the morphological change on the surface.
6.2.5 Drug Release Test
Twenty five milligram HNT/(PVP/PAA)9 /NFT or reformed nylon composite 
containing 25 mg HNT/(PVP/PAA)9/NFT were immersed into 5 ml DI water. The 
suspension was kept shaking for 1 0  minutes, and then centrifuged to collect the 
supernatant for UV-Vis absorbance measurement. Residual supernatant was removed, 
and fresh DI water was replenished. The process was repeated until slight amounts of 
NFT were detected. NFT was assessed by spectroscopic measurement at 370 nm.
6.2.6 Test Bacterium
For in vitro studies E. coli was used. The test strain was susceptible to NFT (MIC 
32 ug/ml). E. coli was cultured within LB broth at 37 °C before testing.
6.2.7 Anti-Proliferation Tests
E. coli cells were resuspended in regular LB broth and adjusted to 1 * 108 cfu/ml 
by O D 6oo measurement. Then bacterial suspensions ( 3  ml) with regular broth and test 
samples (Grouping seen in Table 6-1) were prepared in sealed plastic capillaries. Samples 
were incubated for 6  hours at 37 °C, and OD 6 0 0  spectroscopic measurement was used to 
determine the changes o f cellular density in each sample.
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Table 6-1: G ro u p in g  o f  sam p les  fo r an ti-p ro life ra tio n  test.
Groups Abbreviation Standing for
Control C Blank Control
Sample 1 H Pure HNTs
Sample 2 HP HNT/(PVP/PAA),
Sample 3 HPN HNT/(PVP/PAA)9/NFT
Sample 4 N Nylon- 6
Sample 5 HPn HNT/(PVP/PAA)»/Nylon- 6
Sample 6 HPNn HNT/(PVP/PAAVNFT/Nylon- 6
6.3 Results
6.3.1 Standard Calibration Curve for NFT
As the nanodrop 2000c only has reliable accuracy when the absorbance value lies 
between 0  and 1 , samples with high concentration were diluted before absorbance 
measurement. Table 6-2 and Figure 6-1 show the results o f  the standard calibration 
curve for NFT. A clear linear relation between NFT concentration and absorbance value 
was built within the spectroscopic range between 0 and 1, which is reliable (R 2 =0.999) 
and was used for other tests.
Table 6-2: Standard calibration curve for NFT (wavelength: 370 nm).
Concentration
(ug/ml)
.5 1 . 0 1.5 2 . 0 2.5 3.0 3.5 4.0 4.5 5.0
Absorbance
Value
.037 .076 .113 .154 .193 .229 .272 .308 .345 .384
Standard
Curve
y = ,077x - .001 (R 2 = .999, y-absor 
(ug/rr
aance value, x-NFT concentration 
d))
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Standard Calibration Curve of Nitrofurantoin
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Figure 6-1: Standard Calibration Curve for NFT. A reliable (R 2=.999) linear relation 
between NFT concentration (ug/ml) and absorbance (370 nm) value showed up within 
the spectroscopic range o f  0  to 1 .
6.3.2 Light Sensitivity Test for NFT
The light sensitivity test lasted three days (Table 6-3), and a declining trend o f 
absorbance value could be clearly seen (Figure 6-2), which means NFT would degrade 
slowly on light exposure. S analysis was applied, and the result shows that the sample 
had been statistically different from its original status since the second day. On the other 
hand, it also shows that NFT could not degrade completely in 24 hours. The majority o f  
NFT molecules stayed in solution (Table 6-3). For practical purposes, the degradation 
could be ignored if  all the required processes could be finished in one day.
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Table 6-3: L ight sensitiv ity  test for N F T  (w aveleng th : 370 nm ).
Day-0 Day-1 Day-2 Day-3
Sample 1 .613 .587 .583 .565
Sample 2 .612 .600 .588 .569
Sample 3 .617 .593 .587 .573
Mean .614 .593 .586 .569
SD .003 .007 .003 .004
P N/A . 0 0 2 . 0 0 0 . 0 0 0
(1) One-way ANOVA (IBM SPSS 22.0) was used to analyze the statistic difference 
among these data.
(2) SD stands for standard deviation.
(3) All the samples o f  NFT solution were 10 times diluted.
Light Sensitivity Test for NFT
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„  0.59 
|  0.58
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1  0.56
<  0.55
0.54
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Time Point
Figure 6-2: Result o f  light sensitivity test for NFT. A clear declined trend o f  the 
absorbance value is seen, which means NFT degraded slowly because o f light 
exposure.
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6.3.3 Drug Coating
Electron scanning is a direct way to show the morphological change on the 
outside surface o f HNTs after the fabrication process. Pure HNTs (Figure 6-3 A and B) 
showed smooth outside surface, though some tubes had already shown a bright layer 
because o f  absorption o f  water from air which could be seen as kind o f contamination. 
NFT coated HNTs (Figure 6-3 C and D) also showed a bright layer on the outside as the 
arrow pointed. The halloysite particle inflated and the tubular structure disappeared.
Some tubes clumped together, while the majority stayed uncoated, which suggested huge 
loading potential for further fabrication.
Figure 6-3: Electron scanning images o f  HNTs and coated HNTs. (A) and (B) are pure 
HNTs, while (C) and (D) are coated HNTs (HN T/( P V P/P A A )<>/N F T ).
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An indirect method was used to measure the loading amount o f NFT on 
HNT/(PVP/PAA ) 9  composites. 25 mg HNT/(PVP/PAA)</NFT was immersed into 500 ml 
DI water for a complete release o f  NFT. Sample solution was collected, centrifuged, and 
measured by UV-Vis spectroscopy. According to the above relationship between the NFT 
concentration and absorbance value, the result o f .030 could be translated into .403 
ug/ml, and the released NFT was 201.3 ug. In this way, 1 mg HNT/(PVP/PAA)9 /NFT 
was calculated to carry about 8.1 ug NFT.
6.3.4 Drug Release from HNTs
F1NT/(PVP/PAA ) 9  and HNT/(PVP/PAA)9 /NFT composites were directly mixed 
within nylon - 6  solution (formic acid) individually (Figure 6-4 A). After complete 
evaporation o f  formic acid, sample disks (pure nylon-6 , HNT/(PVP/PAAVnylon-6 , and 
HNT/(PVP/PAAVNFT/nylon-6 ) were formed (Figure 6-4 B). 25 mg 
HNT/(PVP/PAA)9/NFT and sample disks which contain 25 mg HNT/(PVP/PAAVNFT 
were immersed into 5 ml Dl water for NFT release test.
Figure 6-4: Incorporation o f nylon - 6  with HNT/(PVP/PAA ) 9  and 
HNT/(PVP/PAA)9/NFT composites. Groups: nylon - 6  (Row A), HNT/(PVP/PAA ) 9  
(Row B), and FTNT/(PVP/PAA)9 /NFT (Row C). After the complete evaporation o f 
formic acid, sample disks formed.
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In Figure 6-5, the release cycles for both HNT/(PVP/PAA)9 /NFT and 
HNT/(PVP/PAA)9 /NFT/nylon - 6  ran 14 times as no more released NFT could be detected 
by the nanodrop. There was a burst release in both o f groups, and the one o f 
HNT/(PVP/PAA)9 /NFT was much higher than the other (Figure 6-5 A). Then the release 
decreased sharply at the second and third cycle, after which it went mildly until the end.
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Figure 6-5: Release test o f  NFT. The total release cycle ran 14 times. (A) shows the 
individual release for each cycle, and (B) shows the total percentage o f  release by each 
cycle.
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In Figure 6-5 (B), HNT/(PVP/PAA)9 /NFT composites had a higher release 
percentage than its nylon - 6  counterpart, which means by the end o f  the test, there was 
still some NFT not released from FfNT/(PVP/PAA)9 /NFT/Nylon-6 , which may help 
increase the release period.
6.3.5 Bacterial Anti-Proliferation Test
In Figure 6-6, (A) and (C) show the initial images o f  the E. coli culture in each 
group. In the groups o f  HNT, HNT/(PVP/PAA ) 9  and HNT/(PVP/PAA)9/NFT, the broths 
were a little turbid because o f  the suspension o f sample powders. While in the other 
groups, the broths were relatively clear. Sample powders and disks were clearly seen in 
the broths.
Figure 6-6: Anti-proliferation test o f  NFT with E. coli. Group description: C^Control, 
H=HNTs, HP=FTNT/(PVP/PAA)9, HPN= HNT/(PVP/PAA)9 /NFT, N= Nylon-6 , HPn= 
HNT/(PVP/PAA)9/Nylon-6 , HPNn= HNT/(PVP/PAA)9 /NFT/Nylon-6 . (A) and (C) 
show the initial images o f  bacterial culture, while (B) and (D) show their images after 6  
hours.
Figure 6 - 6  (B) and (D) show the images o f  E. coli culture o f six hours. Except for 
the groups o f  HNT/(PVP/PAA)9 /NFT and HNT/(PVP/PAA)9 /NFT/Nylon-6 , all the other
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groups present oyster white turbidity, which made them look the same. In group o f 
HNT/(PVP/PAA)9/NFT, the sample powders were seen in the bottom as sediment. It is 
the same with the group o f HNT/(PVP/PAA)i)/NFT/Nylon - 6  where sample disks stayed 
intact within the broth.
Table 6-4 and Figure 6-7 show the result o f spectroscopic measurement o f  the 
broth in each group at 600 nm. After 6  hours, E. coli proliferated very well in the control 
group with a much higher spectroscopic value. In the groups containing tested powders, 
the values in both groups o f HNT and HNT/(PVP/PAA ) 9  were higher than that in fhs 
control group, while it became very low in the group o f  HNT/(PVP/PAA)9 /NFT. In the 
other three groups with tested disks, the values in groups o f  NyIon - 6  and 
HNT/(PVP/PAA)9 /Nylon - 6  were a little lower than the control, and the one in the 
HNT/(PVP/PAA)9 /NFT/NyIon- 6  was much lower, which was also very close to that in 
the initial group.
Table 6-4: Result o f anti-proliferation test o f nitrofurantoin with E. coli.
E. coli 
(Control)
HNT HNT
Polymer
HNT
Polymer
NFT
Nylon-6 HNT
Polymer
Nylon-6
HNT
Polymer
NFT
Nylon-6
Sample 1 .918 .686 1.236 .131 .906 .853 .045
Sample 2 .914 .681 1.215 .129 .891 .858 .044
Sample 3 .935 .661 1.222 .123 .912 .864 .048
Mean .922 .676 1.224 .128 .903 .858 .046
SD . 0 1 1 .013 . 0 1 1 .004 . 0 1 1 .006 .002
(1). OD 6 0 0  value is directly re
(2). The spectroscopic measui
ated to the cellular density o f  E. coli in broth, 
■ement o f the initial E. coli was .040.
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Figure 6-7: Anti-proliferation test o f NFT with E. coli.
Statistical analysis was applied with one-way ANOVA (IBM SPSS Statistics 22). 
The initial group was not included in the results as it is not normally distributed. A 
Shapiro-W ilk’s test (P>.05) showed that the spectroscopic values were approximately 
normally distributed for all the groups. A Levene’s test verified the equality o f variances 
in the samples (homogeneity o f variance) (P>.05). In Table 6-5: Statistical analysis o f  
anti-proliferation test., only the groups o f  control and Nylon - 6  were statistically same, 
while all the others were different. Additionally, the spectroscopic value in the group o f 
HNT/(PVP/PAA)9 /NFT/Nylon - 6  was very close to that o f  the initial, which suggested the 
bacterial proliferation was completely inhibited.
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Table 6-5 : S ta tistica l ana lysis  o f  an ti-p ro life ra tio n  test.
C H HP HPN N HPn HPNn
c N/A .000 .000 .000 .199 .000 .000
n .000 N/A .000 .000 .000 .000 .000
HP .000 .000 N/A .000 .000 .000 .000
HPN .000 .000 .000 N/A .000 .000 .000
N .199 .000 .000 .000 N/A .001 .000
HPn .000 .000 .000 .000 .001 N/A .000
HPNn .000 .000 .000 .000 .000 .000 N/A
Sample size n=3
6.4 Discussion
6.4.1 Strategy Novelty
Surgical site infection (SSI) is a common postoperative complication in surgery, 
which may cause serious consequent to patients in both finance and health. A routine and 
efficient way to prevent SSI is the application o f  antibiotics during the perioperative 
period, which mainly includes enteral administration and parenteral route. In the former 
class, there are three methods o f administration including oral, sublingual, and rectal. 
Drugs given by enteral administration (except rectal way) are subjected to significant first 
pass metabolism through the liver, and the amount o f drug entering the systemic 
circulation would vary significantly for different individuals and drugs [62]. In the 
parenteral course, drugs can be given through veins, arteries, muscles, spinal canal, and 
skins. After entering the systemic circulation, drugs will be distributed evenly in the 
blood stream around the whole body. Only a small fraction o f drug molecules are 
delivered to sites where their actions are expected, and the rest can expose normal tissues 
to risk o f  side reactions.
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The application o f HNTs based drug delivery system can change this situation. 
Nitrofurantoin was used in this project as an example. On the one hand, NFT could be 
directly released from temporary body implants (like sutures, staples, glues and tapes) to 
sites o f action, which can greatly improve drug efficiency. On the other hand, 
unnecessary exposure o f  NFT to regular tissues can be avoided, and patients will not 
suffer from any side reaction.
Another benefit o f this strategy comes from the extension o f drug application. In 
this project, NFT has good activity against many bacteria including E. coli, S. aureus, and 
E. faeca l is, which are also included in the list o f common pathogens for surgical site 
infection. Besides, NFT has a preference o f  bacterial cells over mammalian cells, and 
acquired resistance in sensitive bacteria is relatively rare. However, its clinical 
application is limited to urinary tract infection because o f some limitations like low 
bioavailability, poor tissue penetration, and fast metabolism by liver [60], By applying 
the strategy o f directly delivering NFT to sites o f action, all the above problems 
disappeared and NFT became a good alternative for the prevention o f SSI.
6.4.2 Advantage o f  Laver-bv-Laver Coating
In Chapter 4, three common methods have been compared, and the layer-by-layer 
technique showed better performance in both drug loading and releasing than the other 
two. Therefore, the LbL technique was used for the fabrication o f  HNT based drug 
delivery vehicle in this experiment. Theoretically, the built LbL structure on the outside 
surface o f  HNTs could be used to trap NFT molecules, and the more layers there were, 
the more molecules would be held inside the LbL base. Meanwhile, the release period 
would be extended correspondingly with the increased layers.
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The LbL technique is an easy and cheap process with no specially required 
equipment. The drug layer could be placed anywhere inside the LbL structure according 
to the application goal. In this preliminary experiment, as NFT was the only tested drug, 
it was placed on the most outside layer to 1) achieve a burst release at the start o f the 
release process and reach the required drug concentration for NFT’s antibiotic action 
(MIC90 for E. coli is 32 ug/ml [63]), 2) avoid unnecessary loss o f NFT in process o f 
adding extra layers. W hat’s more, one drug could be theoretically incorporated multiple 
times during the fabrication process, and more than one drug could be included in the 
LbL design.
6.4.3 Release Properties
An ideal drug delivery system should not release drugs too fast or too slow. 
Released drugs need to stay above a required concentration to take action, and the status 
should continue until achievement o f  the expected result. The HNTs based drug delivery 
system showed a potential for such properties in release tests. The main driving force for 
the NFT release was the concentration gradient between D1 water and HNT/polymer 
nanoparticles. Once entering aqueous solution, NFT molecules started to move, and the 
net direction was from HNT to DI water, which was opposite to that in the fabrication 
process. This trend lasted until a balance was reached, where the net moving o f NFT 
molecules stopped. After the replenishment with fresh DI water, a new concentration 
gradient, which was smaller than the prior one, formed between HNT and DI water 
leading to another cycle o f  NFT release. In this way, the release period was partially 
determined by the consuming rate o f  drugs by surrounding environment. The 
concentration gradient also determined the release rate, which could well explain the fast
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release at the initial stage and slow release at the end. Besides, the LbL structure could 
also affect the release process, as NFT molecules trapped between different layers might 
present different release spans. Finally, by comparing the release results o f 
HNT/(PVP/PAA)9/NFT and HNT/(PVP/PAA)9/NFT/Nylon-6, the filling o f  coated HNT 
into nylon-6 could help slow down rather than inhibit the release process. This property 
enabled the HNT delivery system have more potential in nylon-6 based applications.
6.4.4 Anti-Proliferation Test with E. coli
In F igure 6-7, the increased OD 6 0 0  value in the control group, compared with the 
initial, showed the bacterial growth during the past 6 hours. To avoid the sediment o f 
bacterial cells, no centrifuge operation was done with the samples. Although left standing 
for a while, there were still some HNTs or coated HNTs suspending in the broth which 
may affect the spectroscopic measurement o f  the bacterial density.
In the groups o f HNTs and coated HNTs, their OD 6 0 0  values represented the 
absorbance o f  both E. coli and HNTs or coated HNTs. Fortunately, in the group o f 
HNT/(PVP/PAA)9/NFT whose OD 6 0 0  values was .128 ± .004, it suggested that the 
increased OD 6 0 0  values caused by HNTs or coated HNTs should be smaller than .128. 
Given the values in the group o f  HNTs (1.676 ± .013) and HNT/(PVP/PAA)9( 1.224 ± 
.011), the bacterial growth should not have been inhibit. Instead, the bacterial growth was 
stimulated to increase to some degree. At least, both HNT and HNT/(PVP/PAA)9were 
not harmful to E. coli. Compared with the control group o f  E. coli, the decreased value in 
group o f  HNT/(PVP/PAA)9/NFT was caused only by the release o f NFT. There was also 
a significant decrease in the group o f  HNT/(PVP/PAA)9 when compared with group o f 
HNT. The reason could be the pH change caused by polymer layers because they were
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fabricated in a strong acid environment (pH=3), which compromised the stimulant effect 
o f HNT on E. coli.
In the rest groups o f  nylon-6 , HNT/(PVP/PAA)9 /Nylon-6 , and 
HNT/(PVP/PAA)9 /NFT/Nylon-6 , the values only represented the growth o f  bacteria as 
the coated HNT powders were filled in the nylon - 6  matrices rather than suspended in the 
broth. The values in the group o f nylon - 6  were statistically the same as that o f  the control 
group, which proved that the nylon - 6  disks in the broth did not affect the bacterial growth 
in the past six hours. Although formic acid has been reported to be very efficient in 
reducing the population o f E. coli [64] and it was used to prepare the solution o f nylon-6 , 
the result in Group nylon - 6  could well confirm the complete evaporation o f  formic acid 
during fabrication process.
On this basis, the slight decrease in the group o f  HNT/(PVP/PAA)9/Nylon - 6  could 
be due to the pH change caused by the coated polymers, and the huge difference between 
the group o f HNT/(PVP/PAA)9 /NFT/Nylon - 6  and the control was only caused by the 
released NFT. To be more specific, the spectroscopic value in the group o f 
HNT/(PVP/PAA)9/NFT/Nylon - 6  (.046 ± .002) was just slightly higher than that o f  initial 
E. coli (.040) as NFT could well inhibit bacterial proliferation but not kill them.
6.4.5 Challenge
During the fabrication o f layer-by-layer structure, the coated HNT particles could 
easily clump together, which may stop further coating o f more layers. As seen in F igure 
6-3 (C) and (D), even after the process there were still a lot o f HNTs staying uncoated. 
Therefore, more study is required to increase the ratio o f coated HNT versus uncoated 
ones, which reserves a huge room for the drug loading improvement.
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6.5 Conclusions
Hailoysite nanotubes did not provoke a cytotoxic effect on E. coli cells nor inhibit 
their proliferation ability. Nitrofurantoin was incorporated into a PE coating and observed 
released from the coating. Released NFT resulted in a reduction in bacterial proliferation. 
After the NFT-coated HNTs were mixed with Nylon-6 , the releasing ability o f NFT was 
preserved, and the released NFT also inhibited bacterial proliferation. As a 
nanocomposite drug delivery system, NFT coated HNTs show a potential for the delivery 
o f antibiotic drugs. While NFT was the drug used in this study, there is also a potential 
for the system to incorporate other drugs. The system also has the potential to insert drugs 
at different coating depths that may permit multiple, combinatorial or even sequential 
release depending on coating architecture and composition.
CHAPTER 7 
CONCLUSIONS AND FUTURE W ORK
7.1 Conclusions
In this dissertation, halloysite nanotubes were studied as nano-carriers to load and 
release drugs (methotrexate and nitrofurantoin) for potential clinical applications. Three 
common fabrication methods were compared including physical adsorption, vacuum 
loading, and layer-by-layer coating. The drug loaded halloysite composites were filled 
within nylon-6 , and continuously provided a sustained release o f loaded drugs. In vitro 
osteosarcoma cell test and in vitro E. coli test confirmed the intact biological functions o f 
released drugs. In this way, the halloysite based drug delivery system showed a potential 
medical application and provided another option for drug delivery.
Physical adsorption and vacuum loading are common methods used for HNT 
fabrication, while layer-by-layer coating was studied as a novel method to prepare the 
HNT based drug delivery vehicle. Methotrexate was used as the model drug to be 
delivered, and the LbL coating method had better performance than the other two in both 
loading and releasing. Therefore, LbL coating was used for drug loading in subsequent 
experiments.
Osteosarcoma is the most common malignant bone cancer in children and 
adolescents, and local relapse was a main cause o f death after surgical remove o f the
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primary tumor mass. One important strategy is to prevent postoperative recurrence, 
which is the main target o f  the newly formed HNT-based drug delivery system. LbL 
technique was applied, and MTX was loaded within the LbL layers. Then the MTX 
coated HNTs composites were added within nylon - 6  as fillers. Pure HNTs and 
HNT/PE/nylon composites did not provoke a cytotoxic effect on osteosarcoma cell nor 
inhibit their proliferation ability, but the released MTX caused significant decrease in cell 
proliferation. Even after the MTX coated HNTs were mixed within nylon-6 , the releasing 
ability o f  MTX was preserved, and its anti-proliferation function was kept intact. As a 
nanocomposite drug delivery system, MTX coated HNTs showed a potential to deliver 
antitumor drugs directly to sites o f  action to prevent future relapse. The system also holds 
a potential to incorporate other drugs at different coating depths that may permit multiple, 
combinatorial, or even sequential release depending on coating architecture and 
composition.
Surgical site infection is a common and feared complication. It can cause 
considerable consequences for patients and high medical costs for society. One potential 
strategy to improve the current treatment result is to enhance the efficacy o f  routine 
antibiotics. The nitrofurantoin coated HNTs drug delivery system provides such an 
option. NFT coated HNTs presented a burst initial release followed by sustained mild 
drug liberations in DI water. After being filled in nylon-6 , the releasing ability was 
preserved and the release became milder and longer. In the in vitro bacterial anti­
proliferation test, the NFT coated HNT showed efficient inhibition on the bacterial 
growth, suggesting a potential in the prevention o f  SSL
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7.2 Future Work
7.2.1 Improving Loading Efficiency
Under routine laboratory condition, one hard challenge with the HNT fabrication 
is to improve the loading efficiency. In both Figure 4-2 and Figure 6-4, it clearly showed 
that a big ratio o f HNTs stayed uncoated after fabrication. Regular vortex machine and 
shaker cannot completely separate the nanoparticles after centrifuge, leaving them in 
clumps. Therefore, there is still a huge space for further coating, which holds a potential 
for increasing the drug loading ability. Maybe a high frequency sonicater is a possible 
solution? However, its impact on the layer-by-layer structure needs to be considered as 
well.
7.2.2 Tunable Laver-bv-layer Fabrication
The layer-by-layer fabrication method is an easily controllable process, as each 
layer’s coating is an independent process. Factors like polyelectrolytes, concentration, 
pH, and solvent can greatly impact the properties o f  the built layer-by-layer structure. It is 
potential to endow the LbL structure different properties by tuning these factors.
7.2.3 Multiple and Sequential Drug Delivery
Theoretically, there is little limitation in the layer-by-layer coating. The target 
drug could be coated at any depth within the LbL structure, and multiple drugs could be 
coated at different depths. Therefore, there is a potential for multiple and sequential drug 
delivery with the HNT based system. Further studies o f  the release profile for the 
sequential drug release will continue in Dr. M ills’ lab.
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7.2.4 In Vivo Animal Test
Preliminary in vitro tests with both osteosarcoma cells and E. coli have 
individually confirmed the feasibility o f  applying HNTs based drug delivery system in 
the treatment o f  cancer and surgical site infection. To further verify the hypothesis about 
the practical potential o f HNT based drug delivery system, animal test is required. 
Potentially target medical supplies like bone cement, sutures, and tissue scaffold could be 
made through technologies including electrospinning, electrospray, and 3-D printing. 
Chemotherapeutics, antibiotics, and hormones could be loaded with HNT based system 
and then filled within aforementioned medical products. Animal models are planned to 
test the feasibility o f drug delivery through HNT based systems.
This dissertation presents three simple methods for drug delivery with halloysite 
nanotubes. Two preliminary in vitro tests were showed to foresee potentially future 
application in medical field. I hope these studies could provide another option for the 
research in drug delivery.
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